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ABSTRACT 
 
X chromosome inactivation (XCI) is a gene dosage compensation mechanism that 
results in transcriptional silencing of one of the two X chromosomes in female cells. 
Polycomb repressive complexes PRC1 and PRC2 play essential roles in the process, 
through deposition of repressive epigenetic marks H2AK119ub and H3K27me3, 
respectively. Nuclear matrix protein CIZ1, which has established links with diseases 
such as cancer, plays a role in initiation of mammalian DNA replication through 
interaction with cyclin-dependent kinases. Recently it has also been observed to 
localize to the inactive X chromosome and loss of the protein results in disruption of 
the long non-coding RNA Xist. In mice, loss of CIZ1 leads to development of a 
lymphoma-like phenotype in female mice. My project has used RNAseq analysis, 
immune-detection techniques, and transfections to investigate the relationship 
between CIZ1 and X inactivation.  I present evidence that implicates the C-terminus 
end of CIZ1 in binding at the Xi region and the N-terminus in recruitment of the protein 
to the Xi.  I have also shown that loss of CIZ1 leads to disruption of the H3K27me3 
at the Xi. At the gene expression level, absence of CIZ1 does not lead to any evident 
gene reactivation from the inactive X or changes in expression of genes at the X 
inactivation centre (Xic). However, whole-genome analysis showed that loss of CIZ1 
does in fact lead to highly significant changes in the expression of PRC1 and PRC2 
target genes, while leaving PRC1 and PRC2 subunits unaffected. This data suggests 
that loss of CIZ1 causes widespread changes in gene expression, which could 
underlie the lymphoma-like phenotype in female mice, and begins to suggest a 
mechanism of action for CIZ1 that involves recruitment of template to sites of 
polycomb action.  
 
 
 
 
 
 
 
 
 
 
 
	
	
	
	
	
	
3	
TABLE OF CONTENTS 
 
ABSTRACT .................................................................................................... 2	
TABLE OF CONTENTS ................................................................................. 3	
LIST OF TABLES .......................................................................................... 7	
LIST OF FIGURES ......................................................................................... 8	
ACKNOWLEDGEMENTS .............................................................................. 9	
AUTHOR’S DECLARATION ........................................................................ 10	
CHAPTER 1. INTRODUCTION .................................................................... 11	
1.1	 X CHROMOSOME INACTIVATION ......................................................... 11	
1.1.1	 Initiation ........................................................................................... 12	
1.1.2	 Spreading and recruitment of polycomb repressive 
complexes ....................................................................................................... 13	
1.1.3	 Maintenance .................................................................................... 15	
1.2	 XIST AND THE NUCLEAR MATRIX ........................................................ 16	
1.3	 CIP1 INTERACTING ZINC FINGER PROTEIN (CIZ1) ................................ 17	
1.4	 CIZ1 AND XIST ................................................................................. 20	
CHAPTER 2. MATERIALS AND METHODS .............................................. 21	
2.1	 CELL LINES ...................................................................................... 21	
2.1.1	 Cell line information ....................................................................... 21	
2.1.1.1	 Design and generation of Ciz1 KO cell lines (Justin Ainscough) ......................... 21	
2.1.1.2	 Design and generation of e13.17 Ciz1 KO cell line (Justin Ainscough) ............... 22	
2.1.2	 Media ................................................................................................ 22	
2.1.3	 Maintenance .................................................................................... 22	
2.2	 TISSUE SAMPLES .............................................................................. 23	
2.3	 RNA EXTRACTION ............................................................................ 23	
2.4	 QUANTITATIVE PCR (QPCR) ............................................................ 23	
2.5	 WHOLE TRANSCRIPTOME RNA SEQUENCING ...................................... 24	
2.5.1	 Analysis of RNA integrity ............................................................... 24	
2.5.2	 cDNA library preparations ............................................................. 25	
2.5.3	 Sequencing ...................................................................................... 25	
	
	
	
	
	
	
4	
2.5.4	 Bioinformatics analysis .................................................................. 26	
2.5.5	 Data interpretation .......................................................................... 27	
2.5.6	 Gene set enrichment analysis (GSEA) .......................................... 28	
2.5.7	 Heatmaps ......................................................................................... 29	
2.6	 IMMUNOFLUORESCENCE ................................................................... 29	
2.6.1	 Antibodies ....................................................................................... 29	
2.6.2	 Imaging ............................................................................................ 30	
2.7	 NUCLEAR MATRIX EXTRACTION .......................................................... 30	
2.8	 PLASMID DNA TRANSFECTION .......................................................... 31	
CHAPTER 3. IMPORTANCE OF CIZ1 DOMAINS FOR ITS TARGETING TO 
THE INACTIVE X ......................................................................................... 33	
3.1	 INTRODUCTION ................................................................................. 33	
3.2	 AIMS ............................................................................................... 33	
3.3	 EXPERIMENTAL DESIGN ..................................................................... 34	
3.4	 RESULTS ......................................................................................... 34	
3.4.1	 Full-length GFP-CIZ1 forms high-density patches at the Xi with 
high efficiency ................................................................................................ 34	
3.4.2	 C-terminus analysis shows binding at the Xi ............................... 35	
3.4.2.1	 The C-terminal end of CIZ1 contains the sequences required for 
accumulation of CIZ1 at the Xi .............................................................................. 35	
3.4.2.2	 Investigating dependence of the C-terminus construct on 
endogenous CIZ1 to accumulate at the Xi ........................................................... 36	
3.4.3	 N-terminus analysis shows dominant negative effect on 
endogenous CIZ1 ........................................................................................... 39	
3.4.3.1	 N572 GFP-CIZ1 is unable to form high-density patches at the Xi but 
interferes with the presence of endogenous CIZ1 at the Xi ............................... 39	
3.4.3.2	 The GFP-eCIZ1 variant of N572 construct lacks the sequences 
involved in the interference mechanism .............................................................. 39	
3.4.4	 Transfection of human constructs ................................................ 43	
3.4.4.1	 CIZ1 b-variant does not display a significantly different ability to 
form high-density patches at the Xi compared to full-length human CIZ1 ....... 43	
3.4.4.2	 F-variant CIZ1 is unable to form high-density CIZ1 patches at the 
inactive X 44	
3.5	 DISCUSSION ..................................................................................... 46	
	
	
	
	
	
	
5	
CHAPTER 4. ANALYSIS OF THE RELATIONSHIP BETWEEN CIZ1 AND 
H3K27ME3 ................................................................................................... 50	
4.1	 INTRODUCTION ................................................................................. 50	
4.2	 AIMS ............................................................................................... 50	
4.3	 EXPERIMENTAL DESIGN ..................................................................... 50	
4.4	 RESULTS ......................................................................................... 51	
4.4.1	 Ciz1 KO causes disruption of the H3K27me3 methylation mark 
at the Xi 51	
4.4.2	 Re-expression of Ciz1 in a Ciz1 KO background leads to 
reinstatement of the methylation mark ........................................................ 52	
4.4.3	 Reinstatement of the H3K27me3 mark is initially delayed in non-
cycling cells .................................................................................................... 54	
4.5	 DISCUSSION ..................................................................................... 56	
CHAPTER 5. GENOME-WIDE EXPRESSION ANALYSIS ......................... 59	
5.1	 INTRODUCTION ................................................................................. 59	
5.2	 AIMS ............................................................................................... 59	
5.3	 EXPERIMENTAL DESIGN ..................................................................... 59	
5.4	 RESULTS ......................................................................................... 60	
5.4.1	 Preliminary work for RNA sequencing analysis .......................... 60	
5.4.1.1	 Selection of cell lines for RNA sequencing samples ............................... 60	
5.4.1.2	 Testing ability of the e13.17 KO cell line to express GFP-CIZ1 upon 
induction with doxycycline ........................................................................................ 62	
5.4.1.3	 Investigating the effects of doxycycline concentration on induction of Ciz1 
expression ................................................................................................................ 63	
5.4.1.4 RNA integrity analysis .................................................................................. 65	
5.4.2	 Analysis of Ciz1 expression .......................................................... 67	
5.4.3	 Analysis of RNA sequencing data from X chromosome ............. 68	
5.4.3.1	 Analysis of gene expression from the X chromosome ............................ 68	
5.4.3.2	 Genes from the X inactivation centre are not significantly affected as a 
consequence of Ciz1 KO .......................................................................................... 71	
5.4.3.3	 Female and male mouse cell lines show different response to Ciz1 KO 72	
5.4.3.4	 Re-expression of Ciz1 in a Ciz1 KO cell line restores wild-type levels of 
gene expression for some genes ............................................................................. 73	
5.4.3.5	 Comparative analysis of X-linked genes affected by loss of CIZ1 
with existing literature on X inactivation .............................................................. 75	
5.4.4	 Analysis of RNA sequencing data from the whole genome ....... 77	
	
	
	
	
	
	
6	
5.4.4.1	 Overview of gene expression from the whole genome ........................... 77	
5.4.4.2	 The list of genes that are significantly affected by knockout of Ciz1 in the 
whole genome is enriched for PRC1 and PRC2 target genes ................................. 78	
5.4.4.3	 Genes affected by knockdown of BMI1 are differentially affected in 
female and male cell lines ........................................................................................ 83	
5.4.4.4. Re-expression of Ciz1 in a Ciz1 KO background reinstates wild-type levels 
of gene expression for some genes ......................................................................... 84	
5.4.4.5	 Genes affected by knockdown of BMI1 are good candidates for the 
female specific lymphoma ........................................................................................ 86	
5.4.4.6	 Immune function related genes are also affected by knockout of Ciz1 ... 88	
5.4.4.7 Summary section of other interesting results of gene ontology analysis ...... 89	
5.5	 DISCUSSION ..................................................................................... 90	
CHAPTER 6. DISCUSSION ......................................................................... 95	
LIST OF ABBREVIATIONS ......................................................................... 98	
REFERENCES ............................................................................................. 99	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	
	
	
	
	
	
7	
LIST OF TABLES 
 
 
CHAPTER 2 
 
Table 2.1 ……………21  
Table 2.2 ……………21 
Table 2.3 ……………23 
Table 2.4 ……………24 
Table 2.5 ……………25 
Table 2.6 ……………26 
Table 2.7 ……………27 
Table 2.8 ……………28 
Table 2.9 ……………29 
Table 2.10 ……………31 
Table 2.11 ……………32 
 
CHAPTER 5 
 
Table 4.1 ……………52 
 
CHAPTER 5 
 
Table 5.1 ……………68 
Table 5.2 ……………69-70 
Table 5.3 ……………76 
Table 5.4 ……………77-78 
Table 5.5 ……………79 
Table 5.6 ……………79 
Table 5.7 ……………83 
Table 5.8 ……………90  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
	
	
	
	
8	
LIST OF FIGURES  
 
 
CHAPTER 1 
Figure 1.1 ……………12 
Figure 1.2 ……………15 
Figure 1.3 ……………18 
Figure 1.4 ……………19 
 
CHAPTER 2 
Figure 2.1 ……………22 
Figure 2.2 ……………30 
Figure 2.3 ……………31 
 
CHAPTER 3 
Figure 3.1 ……………33 
Figure 3.2 ……………34 
Figure 3.3 ……………36-37 
Figure 3.4 ……………38 
Figure 3.5 ……………38 
Figure 3.6 ……………40-41 
Figure 3.7 ……………41-43 
Figure 3.8 ……………44-45 
Figure 3.9 ……………45-46 
Figure 3.10 ……………47 
 
CHAPTER 4 
Figure 4.1 ……………51 
Figure 4.2 ……………53 
Figure 4.3 ……………54 
Figure 4.4 ……………55 
Figure 4.5 ……………56 
 
CHAPTER 5 
Figure 5.1 ……………60 
Figure 5.2 ……………63 
Figure 5.3 ……………64-65 
Figure 5.4 ……………66 
Figure 5.5 ……………66 
Figure 5.6 ……………70 
Figure 5.7 ……………71 
Figure 5.8 ……………72 
Figure 5.9 ……………73 
Figure 5.10 ……………74 
Figure 5.11……………81 
Figure 5.12 ……………82 
Figure 5.13 ……………84 
Figure 5.14 ……………85 
Figure 5.15 ……………86 
Figure 5.16 ……………87 
Figure 5.17 ……………88
ACKNOWLEDGEMENTS 
 
This research was carried out with support of the University of York, which provided 
funding for the RNA sequencing work, and the Radhika Scholarship Fund, who 
provided me with the necessary funds to complete the last few months of my Masters. 
I would also like to express my gratitude to Sally James, Dr. Richard Randle and Dr. 
Peter Ashton for their technical support for the RNA sequencing and bioinformatics 
work. 
 
I would like to thank my supervisor Dr. Dawn Coverley for her constant support, 
enthusiasm and great advice. I would also like to thank Dr. Justin Ainscough for his 
technical assistance and insightful discussions. I have thoroughly enjoyed my time in 
the Coverley lab and would like to thank all of its members, present and past, for such 
an enjoyable experience.  
 
Most importantly, I would like to thank my parents and sisters, for their unconditional 
love, support and patience.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
	
	
	
	
10	
AUTHOR’S DECLARATION 
 
I declare that this thesis is a presentation of original work and I am the sole author. 
This work has not previously been presented for an award at this, or any other, 
University. All sources are acknowledged as References. All the research in this 
thesis is my own, with the following exceptions: 
 
All primary embryonic cell lines (PEFs) were generated by Justin Ainscough. 
 
Chapter 3: 
All GFP-CIZ1 mouse constructs were provided by Dr. Justin Ainscough (Coverley lab) 
Human GFP-CIZ1 constructs were provided by Dr. Dorian Swarts (Coverley lab) and 
Gillian Higgins (Coverley lab).  
 
Chapter 4: 
Reagents for nuclear matrix extraction protocol of cells on coverslips, previous to 
immunofluorescence, were kindly provided by Emma Stewart. 
 
Chapter 5: 
Preparation of cDNA libraries for sequencing was carried out by Sally James 
(Technology Facility, University of York) 
 
Illumina Sequencing was done at the Leeds Institute for Molecular Medicine (LIMM) 
at St. James’s University Hospital in Leeds.  
 
Initial bioinformatics processing, including alignment of reads to the mouse genome, 
transcriptome assembly and differential gene analysis was carried out by Dr. Richard 
Randle Boggis with support of Dr. Peter Ashton (Technology Facility, University of 
York).  
 
 
 
 
 
 
 
	
	
	
	
	
	
11	
CHAPTER 1. INTRODUCTION 
 
 
1.1 X chromosome inactivation 
	
X chromosome inactivation (XCI) is the mechanism by which one of the two X 
chromosomes in female cells is inactivated. This process evolved in eutherian 
mammals in order to establish a gene dosage compensation mechanism between 
the sexes (Gribnau and Grootegoed, 2012); females cells have two X chromosomes 
(XX) while male cells have only one (XY). A key element in the process of XCI is the 
17kb long non-coding RNA (lncRNA) molecule known as Xist, which is expressed 
from a locus on the X chromosome known as the X inactivation centre (Xic). This 
locus also contains other genetic elements that are necessary for XCI (Galupa and 
Heard, 2015).  
 
Two types of XCI are observed  in mice (Pollex and Heard, 2012). The first one is 
known as imprinted XCI and occurs early in female embryogenesis, transcriptionally 
silencing the paternally derived X chromosome (Xp).  During the blastula stage, the 
Xp is reactivated and this is immediately followed by random XCI (rXCI), the second 
type of XCI. During this stage either the maternal (Xm) or paternal X (Xp) 
chromosome can be inactivated, and the choice is thought to be random. Following 
random XCI the same Xi is propagated in subsequent cell divisions, and is clonally 
maintained. Xist is crucial for XCI in humans as well as mouse, but in humans the 
choice of which X chromosome is inactivated is thought to occur at random also 
throughout development (Moreira de Mello et al, 2010).  
 
Mechanistically, XCI is triggered following expression of Xist from the future inactive 
X chromosome (Xi), followed by accumulation in cis and recruitment of other factors, 
such as Polycomb Repressive Complex 2 (PRC2) and 1 (PRC1), and DNA-
methyltransferases that contribute to silencing (Cerase et al, 2015). Evidence from 
several studies show that Xist contains different conserved repeat domains named A 
to F (Figure 1.1), which are suggested to have distinct roles (Sado and Brockdorff, 
2012) (Galupa and Heard, 2015). Repeats B and F have an essential role in 
recruitment of PRC2 while A-repeat is essential for silencing but not PRC2 
recruitment (da Rocha et al, 2014). 
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important for association of Xist RNA to the X chromosome (Sado and Brockdorff, 
2012). Function of the E-repeats remains unknown.  
 
 
Figure 1.1. Schematic of Xist long non-coding RNA. Schematic shows the repeats present in Xist 
with an indication of their function.  
 
Despite XCI, a small percentage of genes from the inactive X chromosome, known 
as ‘escape genes’ remain transcriptionally active. In the mouse, this set of genes 
represents approximately 3.3% (Yang et al, 2010), while in humans they represent a 
much larger percentage of 15% (Carrel and Willard, 2005). These genes are thought 
to have female-specific functions, working as factors that contribute to sexual 
dimorphism (Berletch et al., 2011). 
 
1.1.1 Initiation 
	
Several key elements are necessary for both the initiation and maintenance of X 
chromosome inactivation, and likely more remain undiscovered. Initiation of random 
XCI begins with the expression of 17kb Xist lncRNA, which occurs following 
downregulation of pluripotency factors such as octamer-binding transcription factor 4 
(Oct4) and Kruppel Like Factor 4 (Klf4). Evidence shows that these pluripotency 
factors can bind to and repress Xist expression while positively regulating Tsix (Jiang 
et al, 2014; Navarro et al, 2008). Tsix is a non-coding gene, which is also located in 
the Xic and is transcribed antisense across Xist, suppressing its transcription (Lee et 
al, 1999). Another two transcribed loci from the X inactivation centre, Jpx and Ftx, as 
well as Xpr (Barakat et al, 2014), are thought to positively regulate Xist, although the 
mechanism is unknown.  
 
Inactivation of the X chromosome is also dependent on a set of trans-acting factors. 
One of the most crucial factors is LIM Domain-Interacting RING Finger Protein 
(Rnf12/RLIM), which acts as an activator of XCI and works in a dosage-dependent 
manner (Jonkers et al, 2009). Evidence also points at a crucial role for this factor in 
imprinted XCI in mice, where maternal germ line deletion of Rnf12 leads to lethality 
of female embryos due to defective XCI (Shin et al., 2010). Jpx, Ftx and Xpr cooperate 
A F B C D E
PRC2 
recruitment
Silencing Association to X 
chromosome
UnknownSilencing
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with and lower the threshold in order for Rnf12 to activate Xist and overcome 
repression by Tsix (Barakat et al, 2014). 
 
The mechanism by which the future inactive X chromosome is chosen during random 
XCI remains unclear despite intense research. Early evidence suggests the existence 
of an initial ‘counting’ mechanism by which the cell is able to determine the number 
of X chromosomes relative to autosomes (Lyon, 1972). This is followed by the ‘choice’ 
of which X chromosome will undergo inactivation and which one will remain active. 
Several different hypotheses that attempt to explain this phenomenon have been 
proposed (Starmer and Magnuson, 2009), with some of the most key ones being 
described below. The ‘blocking factor’ model suggests that an unknown molecule 
named the blocking factor, and produced by autosomes, binds to one of the X 
chromosomes and prevents it from being inactivated, while the active state of the 
remaining degrades, rendering them inactive (Lyon, 1971). The ‘two factor model’ 
builds upon the previous model, but proposes the existence of a competence factor, 
which is produced by both X chromosomes (Lee, 2005). The blocking factor binds 
one of the two competence factors, neutralizing it and rendering that X chromosome 
active, while the other chromosome is inactivated. In the ‘sensing and choice model’  
the process of counting and choice is regulated by elements of the X inactivation 
center (Augui et al, 2007). A mechanism of ‘pairing’ that occurs between the two X 
chromosomes, through the Xpr region, is suggested to play a role in the choice step 
by allowing persistent Tsix expression on the future active X chromosome and thus 
repressing Xist expression. On the future inactive X chromosome on the other hand, 
Tsix expression is downregulated, which leads to expression of Xist (Stavropoulos et 
al, 2005). Overall the process of X chromosome inactivation has been described as 
a complex mechanism where both cis- and trans- regulators control Xist expression 
and activation (Galupa and Heard, 2015).  
 
1.1.2 Spreading and recruitment of polycomb repressive 
complexes 
	
Following choice and counting, Xist is expressed from the future inactive X 
chromosome. Xist transcripts spread in cis- and coat the X chromosome, leading to 
the formation of transcriptionally inactive heterochromatin. Several different 
chromatin modifications are observed at the inactive X. Polycomb repressive 
complexes (PRC) (Figure 1.2) are responsible for some of the characteristic 
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chromatin modifications: PRC1 is responsible for ubiquitination of lysine 119 at 
histone H2A (H2A-K119ub) and PRC2 is responsible for trimethylation of lysine 27 in 
histone 3 (H3K27me3) (Chen et al, 2004). PRC1 and PRC2 can be composed by 
several different subunits, which give rise to PRC1 and PRC2 variants. However, the 
main subunits, which form what is known as canonical PRC1 and PRC2, are indicated 
in Figure 1.2. Despite intense research into this area, the mechanisms underlying 
target specificity and action of these complexes are still incompletely understood. 
Recruitment of PRC2 by Xist is one of the earliest events occurring during X 
inactivation. Alpha Thalassemia/Mental Retardation Syndrome X-Linked protein 
(ATRX), an RNA-binding protein, has been recently identified as a necessary factor 
for the binding of PRC2 to Xist as well as other polycomb targets (Lee et al, 2014). 
Other proteins such as the Jumonji And AT-Rich Interaction Domain Containing 2 
(JARID2), from the Jumonji family of proteins has also been described as cofactors 
involved in the recruitment of PRC2 (da Rocha et al, 2014). Initial observations that 
the PRC1 is able to recognize H3K27me3 via the chromodomain of its chromobox 
homolog (CBX) subunit, led to the idea that PRC2 is recruited first and that, following 
trymethylation, PRC1 is subsequently recruited (Schwartz and Pirrotta, 2014). 
However, recent studies analysing the general mechanism of polycomb recruitment 
in the cell suggest that it is variant PRC1, composed by Really Interesting New Gene 
1 Protein A and B, (RING1A/B), polycomb group ring finger proteins 1 to 6 (PCGF1-
6) and RING1 and YY1 Binding Protein (RYBP), which drives recruitment of PRC2 in 
a H2AK119ub1 dependent manner and that this is followed by recruitment of 
canonical PRC1 (Blackledge et al, 2014). These studies also showed that disruption 
of PRC1 mediated H2AK119ub1 also leads to disruption of PRC2 binding genome-
wide (Schwartz and Pirrotta, 2014).  
 
The study of these polycomb repressive complexes and their functions becomes of 
even greater importance when considering the fact that they have been implicated in 
regulatory pathways that are known to be disrupted in cancer (Jones and Baylin, 
2011). Overexpression of polycomb repressive complexes has been linked with 
several types of cancer, including lung cancer (Sato et al, 2013), breast cancer (Yoo 
et al, 2012) and lymphoma (Raaphorst, 2005).  
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Figure 1.2. Schematic of the composition and function of PRC1 and PRC2. Canonical PRC2 
contains the embryonic ectoderm development (EED) and suppressor of zeste 12 homolog (SUZ12) 
subunits, the histone-binding protein RbAP46/48 and the enhancer of zeste 2 (EZH) subunit, which 
catalyses the methylation at lysine 27 of histone H3 (H3K27me3). Canonical PRC1 includes RING finger 
proteins RING1A/B and the PCGF proteins MEL18 (PCGF2) or BMI1 (PCGF4). They also contain 
chromobox-containing protein (CBX) subunits, which recognize H3K27me3, and polyhomeotic (PHC) 
subunits.  
 
It is not yet clear how the XCI signal spreads along the chromosome, however it has 
been proposed that long interspersed repetitive sequence elements (LINEs) could 
have a role in this process (Lyon, 2000). It has been observed that ectopic expression 
of Xist in autosomes leads to less efficient spreading of Xist and less efficient 
silencing. This suggested the existence of elements in the X chromosome, referred 
to as ’boosters’, that somehow increase the efficiency of the spreading of the 
inactivation signal during XCI (Lyon, 2003). Although enriched in the X chromosome, 
LINES are also present in autosomes, consistent with the fact that autosomes are 
also capable of localized inactivation. In line with this hypothesis the density of LINEs 
appears to be highest in regions near the Xic and lowest in regions where genes are 
known to escape inactivation (Lyon, 2003).   
 
1.1.3 Maintenance 
	
Following random XCI, the inactive X chromosome enters a maintenance phase, 
during which different mechanisms maintain the silent state of the Xi. This phase 
occurs beyond mouse embryonic days 5.5 (Yildirim et al, 2013). 
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Despite the continued expression of Xist, it appears to be dispensable for 
maintenance of the Xi (Brown and Willard, 1994) (Csankovszki et al, 1999), as loss 
does not cause reactivation of gene expression. However, more recent work suggests 
a novel role for both Xist lncRNA and the perinucleolar ring in maintenance of the Xi 
(Zhang et al, 2007). This study provided evidence that following X-X pairing, the Xi 
migrates to the perinucleolar region by an unknown mechanism, and that this direct 
association is also necessary during mid-to-late S phase to ensure that genes from 
the Xi are continuously and faithfully repressed. In addition, results showed that Xist 
is in fact essential for targeting of the Xi to the perinucleolar compartment and that 
loss of Xist, and with it loss of perinucleolar localization, leads to loss of the H3K27 
methylation mark and gene reactivation at the single gene level (Zhang et al, 2007).  
Another player that has been linked to the movement of the Xi to the perinucleolar 
ring is the long non-coding RNA Functional Intergenic Repeating RNA Element 
(Firre), an X-linked gene. Knockdown of Firre leads to disruption of the targeting of 
the Xi to the nucleolus as well as loss of the H3K27 methylation mark (Yang et al, 
2015). 
 
Recent work has uncovered yet another new role for Xist RNA in in vivo suppression 
of cancer (Yildirim et al, 2013). In this study, loss of Xist in the blood compartment of 
mice was observed to cause changes in gene expression and subsequently, 
development of hematological cancer in female mice. This finding, together with other 
observations such as the loss of the inactive X in breast cancer cells (Sirchia et al, 
2005), point towards a possible link between the X chromosome inactivation and 
cancer.  
 
1.2  Xist and the nuclear matrix  
	
One of the most interesting questions about the Xist lncRNA is the mechanism that 
allows it to remain in the nucleus, avoiding nuclear export and specifically coating the 
inactive X chromosome. Despite intensive effort this question remains largely 
unanswered. 
 
A number of different players have been reported to localize to the inactive X 
chromosome, both during initiation and maintenance of XCI. Recent studies have 
uncovered a possible role of the nuclear matrix protein Scaffold Attachment Factor A 
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(SAF-A) in localization of the Xist RNA to the inactive X chromosome (Hasegawa et 
al, 2010). The nuclear matrix, also referred to as nuclear scaffold (Mirkovitch et al, 
1984) or nucleoskeleton (Jackson and Cook, 1988) was first described in the 1960s 
as the non-chromatin structures that can be observed in the nucleus (Fawcett, 1966), 
following observation of extracted cells under an electron microscope. It is currently 
described as an insoluble proteinaceous subnuclear structure that is somewhat 
analogous to the cytoskeleton. This structure has been suggested to act as an anchor 
for several important cellular processes such as DNA replication (Anachkova et al, 
2005), DNA transcription (Robinson et al, 1983) and DNA repair (Koehler and 
Hanawalt, 1996) as well as pre-mRNA splicing (Zeitlin et al, 1987).  
 
An example of the interaction between a nuclear matrix protein and the process of 
XCI comes from the previously mentioned heterogeneous nuclear ribonucleoprotein 
U (hnRNPU), also known as SAF-A, which has been identified as a 120kDa nuclear 
matrix component with high affinity for scaffold attachment regions (SARs) (Romig et 
al, 1992). Studies have also shown enrichment of this protein in the Xi area, which 
showed to be dependent on the RGG box, the RNA binding domain of SAF-A (Helbig 
and Fackelmayer, 2003). Consistent with a role in XCI, knockdown of SAF-A resulted 
in lack of localization of the Xist RNA to the inactive X chromosome as well as 
absence of the H3K27m3, suggesting that it is involved in tethering Xist to the inactive 
X chromosome (Hasegawa et al, 2010). 
 
In addition to SAF-A, our recent evidence, outlined in section 1.4 of this chapter, 
suggests that the nuclear matrix protein Cip1 interacting zinc finger protein 1 (CIZ1) 
may have a role in XCI (Ridings-Figueroa, unpublished). Investigation of the 
functional significance of this observation is the subject of my thesis.  
 
1.3  Cip1 interacting zinc finger protein (CIZ1) 
	
Precise and faithful replication of DNA during S-phase (Figure 1.3) is crucial in order 
to prevent genetic abnormalities that could give rise to disease, death and other 
abnormalities. To ensure this, the cell cycle is subject to a high degree of control and 
safety systems, known as checkpoints, are in place. Key control elements are cyclin-
dependent kinases (CDKs), made up of a kinase subunit and a regulator cyclin 
subunit which activates and targets the kinase, to support phosphorylation of 
appropriate substrates. During G1 phase cyclin Ds associate with CDK4 and CDK6 
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and help transfer information that promotes or inhibits proliferation, leading to 
expression of cyclin E, passage through the restriction point (R) and assembly of pre-
replication complexes. To allow S phase to progress cyclin A substitutes cyclin E as 
the partner of CDK2. For transition into the mitosis phase cyclin B associates with 
CDK1 (Alberts et al, 2008).  
 
 
Figure 1.3. Cell cycle control. Progression through the cell cycle is governed by the interaction of 
cyclin-dependent kinases (CDKs) with their cyclin partners.  
 
CIZ1 has been identified as a nuclear matrix protein and plays an important role in 
the initiation of mammalian DNA replication (Coverley et al., 2005). It was originally 
identified by its ability to bind to the cyclin-dependent kinase inhibitor p21 (Mitsui et 
al., 1999),  which inhibits DNA replication causing cell cycle arrest. It has 
subsequently been reported to interact with CDK2, cyclin E, cyclin A and the pre-
replication complex factor CDC6 (Copeland et al, 2010). CIZ1 has been reported to 
function as a molecular scaffold during DNA replication, allowing coupling of the 
activities of cyclin A and cyclin E. During mid-G1 phase cyclin E interacts with CDK2, 
which allows pre-replication complex (pre-RC) assembly. As the cell cycle progresses 
into late G1 the levels of cyclin A rise and cyclin A displaces cyclin E as the molecular 
partner of CDK2, which leads to activation of the DNA replication machinery and 
progression through S phase (Copeland et al, 2010). In vitro this cyclin exchange 
occurs in association with the N-terminal end (Figure 1.4) of the CIZ1 protein 
(Coverley et al, 2005). The C-terminal part of the protein, on the other hand, tethers 
the CIZ1 protein to the nuclear matrix (Figure 1.4), in a cell cycle dependent manner, 
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allowing the formation of CIZ1 foci that colocalise with replication factories (Ainscough 
et al, 2007). CIZ1 has also been linked with post-replicative functions in male germ 
cell differentiation (Greaves et al, 2012). Together these data suggest that CIZ1 may 
specify the locations in the nucleus where cyclin exchange takes place, or 
alternatively that CIZ1 may be involved in delivering first cyclin E then cyclin A to sites 
of DNA replication. 
 
Figure 1.4. Schematic of the functional domains of CIZ1 protein. The N-terminal end of the protein 
is responsible for the DNA replication activity of the protein, acting as a platform for cyclin exchange. 
The C-terminal end of the protein is responsible for its attachment to the nuclear matrix.  
 
The CIZ1 protein is encoded by 17 exons, which are alternatively spliced. In fact, at 
least twenty-two variants of CIZ1 have been identified, including the isoform known 
as b-variant, which is being developed as a biomarker for early stage lung cancer 
(Higgins et al, 2012). This variant has a shorter alternative to exon 14, which has 
been named 14b (Higgins et al, 2012). CIZ1 has also been linked with other types of 
cancer, which include both paediatric cancers such as Ewing sarcoma (Rahman et 
al, 2007) and adult cancers such as breast cancer (den Hollander et al, 2006). More 
recently CIZ1 has also been linked with hepatocellular carcinoma in promoting both 
tumour growth and metastasis (Wu et al, 2015). It has also been linked with non-
cancer chronic disorders such as Alzheimer’s disease (Dahmcke et al, 2008) and 
cervical dystonia (Xiao et al, 2012).  
 
Interestingly, work done by previous PhD students in the Coverley and Ainscough 
labs, showed that genetic deletion of Ciz1 (Ciz1-KO) leads to development of non-
Hodgkin follicular type lymphoma in 100% of tested female mice, suggesting a role 
as a tumour suppressor (unpublished).  
 
 
CIZ1
C-terminal endN-terminal end
CDK2
CDK2
Cyclin 
E
Cyclin 
A
DNA replication 
activity
Nuclear matrix 
attachment
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1.4  CIZ1 and Xist  
	
Initial experiments carried out in the Coverley lab have shown that when using an 
anti-CIZ1 antibody, such as 1794 (Coverley et al, 2005), high density patches that 
resemble the Barr body can be observed by immunofluorescence and that these high-
density patches colocalise with the H3K27me3 marker (unpublished), characteristic 
of the inactive X chromosome. It has also been shown using fluorescence in situ 
hybridization (FISH) that CIZ1 is required for accurate Xist localization and 
H3K27me3 marker, which disappears in Ciz1-KO derived cells (Ridings-Figueroa, 
unpublished). Re-expression of Ciz1 in a Ciz1 KO cell line can restore both Xist 
localization and the H3K27me3 methylation mark. These results point towards a 
previously unknown role for CIZ1 in the process of X chromosome inactivation. This 
is supported by the finding that CIZ1 interacts with Xist lncRNA, though it is not known 
whether this is a direct or indirect interaction (Chu et al, 2015).  
 
The aim of this project is to investigate the role of CIZ1 in XCI.  I hypothesize that 
CIZ1, alike nuclear matrix protein SAF-A may have a function in tethering of Xist to 
the inactive X. However, absence of CIZ1 is unlikely to have major effects on gene 
expression from the Xi since other nuclear matrix proteins like SAF-A have been 
reported to have similar and likely redundant functions.  My project is divided into 
three approaches, which address related questions: 
 
1. Investigation of which domains of CIZ1 protein are required for recruitment 
and binding at the inactive X.  
2. Confirmation of our evidence in support of loss of and reinstatement of the 
H3K27me3 mark at the Xi, in response to loss and re-induction of Ciz1 
expression.  
3. Analysis, by mean of an RNA sequencing experiment, of the effect that loss 
of Ciz1 has on genes from the X chromosome, and specifically whether Ciz1 
knockout leads to reactivation of genes from the inactive X chromosome and 
whether this could account for the lymphoma-like phenotype observed in Ciz1 
knockout female mice. In addition, data derived from whole-genome analysis 
will be used to obtain information on other functions or biological pathways 
that CIZ1 might be involved in.  
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CHAPTER 2. MATERIALS AND METHODS 
  
2.1 Cell lines 
	
2.1.1 Cell line information 
 
 
Table 2.1. Cell lines used for RNA sequencing experiment. Table represents the list of primary 
mouse embryonic fibroblasts cell lines that were used for RNA extraction and sequencing. Doxycycline 
was added to the e13.17 cell line which contains a doxycycline inducible GFP tagged Ciz1 transgene, 
and to the e13.15 cell line which does not contain the transgene but was used to test for direct effects 
of doxycycline on gene expression.  All cell lines were generated by Justin Ainscough.  
 
 
Table 2.2. Use of other cell lines.  
 
2.1.1.1 Design and generation of Ciz1 KO cell lines (Justin 
Ainscough) 
 
CIZ1 null mice were generated from C57BL/6 ES clone IST13830B6 (TIGM) 
harboring a neomycin resistance gene trap inserted downstream of exon 1. 
Absence of CIZ1 in homozygous progeny was confirmed by qPCR, 
immunofluorescence and immunoblot with CIZ1 N-term antibody 1793. 
	
CELL LINE DERIVATION ♀/♂ GENOTYPE
E14.4 Primary mouse embryonic fibroblasts ♀ Wild-type
E13.1 Primary mouse embryonic fibroblasts ♀ Wild-type
E13.8 Primary mouse embryonic fibroblasts ♀ Wild-type
E14.2 Primary mouse embryonic fibroblasts ♀ Ciz1 KO
E13.15
- dox Primary mouse embryonic fibroblasts ♀ Ciz1 KO
+ dox 
E13.17
- dox Primary mouse embryonic fibroblasts ♀ Ciz1 KO (contains Ciz1
inducible transgene)+ dox
E13.2 Primary mouse embryonic fibroblasts ♂ Wild-type
E13.6 Primary mouse embryonic fibroblasts ♂ Ciz1 KO
CELL LINE DERIVATION ♀/♂ GENOTYPE
3T3 (Coverley et al, 2002) Fibroblasts ♀ Wild-type
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2.1.1.2 Design and generation of e13.17 Ciz1 KO cell line 
(Justin Ainscough) 
	
Primary embryonic fibroblasts (e13.17 Ciz1 KO PEFs) were derived from double 
transgenic mice harbouring responder and activator transgenes on a CIZ1 -/- 
background (Figure 2.1) (Ainscough, unpublished). The responder transgene 
contains regulatable GFP tagged full-length mouse CIZ1 and a LacZ reporter under 
control of a bidirectional minimal CMV promoter. The activator transgene encodes 
reverse-tetracycline regulatable trans-activator (rtTA) under control of the ubiquitous 
ROSA26 promoter. Addition of doxycycline to media induces rtTA-mediated 
activation of GFP-CIZ1 via the responder tetracycline response element (TRE) within 
6 hours (Ainscough, unpublished). The construct and mouse from which cells were 
derived were made by Justin Ainscough.  
 
 
Figure 2.1. Schematic of CIZ1 induction mouse model (KO-I) showing regulated expression of 
full length CIZ1. 
 
2.1.2 Media 
	
Mouse primary embryonic fibroblasts (mPEFs) as well as 3T3 cells (Coverley et al, 
2002) were grown in Dulbecco’s Modified Eagle Medium (DMEM) with 10% foetal 
bovine serum (Cat. No. A15-151) and 1% penicillin/streptomycin.  
 
2.1.3 Maintenance 
	
Cells were grown at 37°C in a humidified atmosphere in 5% CO2 air. Cells were 
usually kept at approximately 80% and passaged when necessary. Passaging was 
done by removing media, washing with warm Dulbeco’s phosphate buffered saline 
GFP-CIZ1
rtTA
CMVCMV TRELacZ
ROSA26
rtTA
rtTA
dox
LacZ CIZ1
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(D-PBS) and then lifting them with 1mL 1x 0.5 % Trypsin-EDTA (10X) (Life 
Technologies, Cat. 15400054). 
 
2.2  Tissue samples 
	
Tissue samples were obtained from the spleen of a WT (No.181) and a Ciz1 KO 
(No.97) female mouse, both at 15 months of age (Ainscough, unpublished) (Table 
2.3). Ciz1 KO mice develop normally but 100% of adult females show enlarged 
spleen, liver and lungs with observable gross lymphoid abnormalities (Albadrani and 
Ainscough, unpublished). These abnormalities were described as consistent with B-
cell lymphoma with T cell infiltration (Roulson, unpublished).  
 
 
Table 2.3. Information on tissue samples used for extraction of RNA for RNA sequencing work. 
RNA samples from these tissues were generated by Justin Ainscough. Although these samples were 
sent for sequencing and data is available no analysis was carried out due to time constraints.  
 
2.3 RNA extraction 
	
RNA homogenization was achieved using 2mL of TRIzol Reagent (Ambion Life 
Technologies, Cat. No.15596-026) per 9cm plate of cells. Phase separation step 
involved addition of chloroform and isolation of aqueous phase followed by RNA 
precipitation with 100% isopropanol and a final RNA wash step with 75% ethanol. 
RNA was then resuspended in DEPC water. All RNA samples for the RNA 
sequencing were then subjected to DNase treatment (Roche, Cat. No. 
04716728001). 
 
2.4 Quantitative PCR (qPCR) 
 
Expression levels of Ciz1 and Xist were analysed using real-time, quantitative PCR. 
Total RNA was extracted from e14.4 WT PEFs and e13.17 Ciz1 KO PEFs. The latter 
were exposed to 10 μg/mL of doxycycline for periods ranging from 6 to 72h. All 
TISSUE 
SAMPLE
DERIVATION ♀/♂ Body weight Spleen weight
Spleen tissue WT 15 month WT 
mouse
♀ 31 grams 110 mg
Spleen tissue KO 15 month Ciz1 KO 
mouse 
♀ 31 grams 1.21 grams
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samples were treated with DNase to remove any DNA contamination. RNA was 
reverse transcribed using SuperScript® III Reverse Transcriptase (ThermoFisher 
Scientific).  Taqman qPCR was carried out using Taqman (Taqman® Fast Universal 
PCR Master Mix, AB, TFS Inc) reagents and already existing gene-specific primers 
for Ciz1 and Xist (Table 2.4), using the AB StepOnePlus™ Real-Time PCR Systems 
available at the Technology Facility at the University of York. The following program 
was used: 95°C for 20 s, followed by 40 cycles of 95°C for 3 s and 60°C for 30 s. Data 
was analysed using the StepOne Software v. 2.3 (AB, TFS Inc). 
  
The relative quantification of gene expression was done using the 2-ddCt formula 
(Schmittgen et al, 2008). The fold changes of gene expression were normalised to an 
internal control gene, in this case, GapdH (not shown). The e14.4 WT was used as a 
calibrator.  
 
Table 2.4. Primer-probe sets used for quantitative analysis.  
 
2.5 Whole transcriptome RNA sequencing 
	
2.5.1 Analysis of RNA integrity 
	
Following RNA extraction and DNase treatment all samples were sent to the 
Technology Facility at the University of York. Quality of the RNA samples was 
analysed by Sally James, using the Agilent 2100 Bioanalyzer. RNA integrity numbers 
are determined by the electrophoretic trace of the RNA and indicate the quality of the 
submitted RNA samples with the highest value,10, indicating intact RNA and the 
lowest number, 1, indicating degraded RNA. For this specific experiment a RIN value 
of 7 or higher was recommended (James, personal communication) which puts all 
but one sample, spleen KO, within a good quality range. 
PRIMER EXON PRODUCT SIZE (bp) ASSAY
Ciz1 10-11 77 Mm00503766_m1
Xist 1-2 65 Mm01232884_m1
GapdH 2-3 107 Mm99999915_g1
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Table 2.5. Summary results from the Bioanalyzer analysis for RNA quality. 
 
2.5.2 cDNA library preparations 
	
1µg of RNA was provided to Sally James, member of the technology facility at the 
University of York, who carried out the library preparations following the NEBNext® 
Ultra™ RNA library Prep Kit for Illumina® manual.  The protocol followed is that for 
use with NEBNext Poly(A) mRNA Magnetic Isolation Module. This protocol uses the 
feature that mRNA have poly(A) tails, while rRNA, which comprises approximately 
90% of RNA within a cell doesn’t have this poly(A) tail. The protocol involves the use 
of specific magnetic beads that use an oligodT tag to bind to mRNA, pulling this out 
and into a magnet, and washing out the remaining rRNA species. The enriched 
mRNA is then subjected to random fragmentation by sonication and priming, 
producing libraries with 250-400bp insert sizes. This is followed by synthesis of cDNA, 
adaptor ligation and PCR enrichment.  
 
2.5.3 Sequencing 
	
The combined libraries were sent to the Leeds Institute for Molecular Medicine 
(LIMM) at St. James’s University Hospital in Leeds, where they were run on a single 
lane of the Illumina 3000 system, using paired-end sequencing (Table 2.6), which 
allows a maximum read length of 150bp from each end.  
 
SAMPLE RNA integrity number (RIN)
E14.4 WT 9.60
E13.1 WT 9.80
E13.8 WT 9.90
E14.2 Ciz1 KO 9.60
E13.15 Ciz1 KO 9.90
E13.15 Ciz1 KO (+dox) 10
E13.17 Ciz1 KO 9.20
E13.17 Ciz1 KO (+dox) 9.60
E13.2 WT (male) 9.70
E13.6 Ciz1 KO (male) 8.70
Spleen WT 7.50
Spleen KO 6.10
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Table 2.6. Summary of number of reads per library. Table shows the number of reads obtained for 
each sample from the Illumina sequencing. Paired-end sequencing was used which results in both 
forward and reverse reads, which correspond with reads from both ends of the fragment. 
 
2.5.4 Bioinformatics analysis 
	
Initial processing of RNA sequencing data by members of the Technology Facility at 
the University of York involved use of STAR software (Dobin et al, 2013) for alignment 
of reads to the X chromosome, using the reference genome of the C57BL/6 mouse 
(Mus_musculus GRCm38 primary assembly, downloaded from Ensembl.org [Access 
date: 4/05/2016]). Cufflinks software was used for transcriptome assembly of the 
mapped reads (Trapnell et al, 2010), (Roberts et al, 2011), followed by differential 
gene expression analysis with Cuffdiff program, which provided quantified levels of 
expression (Trapnell et al, 2013). 
 
The output from Cuffdiff shows a series of values for which an example can be found 
in Table 2.7. In addition, for the purpose of referring to each of the individual entities 
for which Cuffdiff returns an expression value I used the term ‘transcription unit’, 
rather than ‘gene’, since the latter is not an accurate term for non-annotated 
transcripts.  
 
Sample Forward / reverse reads 
S9 - E14.4 WT ♀ 25666486/25666486 
S10 - E13.1 WT ♀ 38425408/38425408 
S11 - E13.8 WT ♀ 34507392/34507392 
S12 - E14.2 KO ♀ 32424390/32424390 
S13 - E13.15 KO  ♀ 30167428/30167428 
S14 - E13.15 KO (+dox) ♀ 36654457/36654457 
S15 - E13.17KO-I (no dox) ♀ 32331645/32331645 
S16 - E13.17KO-I (+dox) ♀ 29412405/29412405 
S17 - E13.2 WT ♂ 31185113/31185113 
S18 - E13.6 KO ♂ 33393640/33393640 
S19 - SPLEEN WT ♀ 29086647/29086647 
S20 – SPLEEN KO  ♀ 34223665/34223665 
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Table 2.7. Example of Cuffdiff analysis output file. The definitions of the terms that appear on a 
typical cuffdiff file have been extracted from the Trapnell Lab website (http://cole-trapnell-
lab.github.io/cufflinks/cuffdiff/) [Accessed 17.08.2016]. An example gene obtained from one of my 
Cuffdiff files has also been included.  
 
 
2.5.5 Data interpretation 
 
For the X chromosome analysis, initial filtering involved exclusion of transcriptional 
units with “no test” or “fail” test status, which indicate that no statistical test could be 
performed and therefore no p-value can be calculated either. This was followed by 
selection of transcriptional units of interest, that is, those with a p-value equal to or 
less than 0.05. Further selection included manual filtering of any transcriptional units 
where no gene expression was recorded for all but one of the samples. This rendered 
a total of 62 transcriptional units from the X chromosome with a p-value equal or less 
than 0.05. A total of 27 transcriptional units within the 62, correspond to non-
annotated genes and therefore possible novel-transcripts, which have been indicated 
with their locus ID. In this particular case, no attention was paid to the significance of 
the q-value since the main aim of this analysis is to look specifically for changes to 
gene expression from the X and possible candidate genes of X reactivation. If further 
analysis was to be carried out on specific genes from the 62 significant p-value list 
validation by qPCR would be necessary.  
Column name Example Definition
Gene_ID XLOC_000004 A unique identifier describing the transcript, 
gene, primary transcript, or CDS being tested
Gene Gm14360 The gene_name(s) or gene_id(s) being tested
Locus X:3461642-3708291 Genomic coordinates for easy browsing to the 
genes or transcripts being tested.
Sample_1 WT Label (or number if no labels provided) of the 
first sample being tested
Sample_2 KO Label (or number if no labels provided) of the 
second sample being tested
Test status
OK Can be one of OK (test successful), NOTEST 
(not enough alignments for testing), 
LOWDATA (too complex or shallowly 
sequenced), HIDATA (too many fragments in 
locus), or FAIL, when an ill-conditioned 
covariance matrix or other numerical 
exception prevents testing.
Value_1 11.151 FPKM of the gene in sample x
Value_2 2.0901 FPKM of the gene in sample y
Log2(fold change) -2.41554 The (base 2) log of the fold change y/x
Test stat -1.59114 The value of the test statistic used to compute 
significance of the observed change in FPKM
p_value 0.0191 The uncorrected p-value of the test statistic
q_value 0.603433 The FDR-adjusted p-value of the test statistic
Significant No Can be either “yes” or “no”, depending on 
whether p is greater then the FDR after 
Benjamini-Hochberg correction for multiple-
testing
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For the whole genome analysis, the main aim was to look for groups of related genes 
with significant changes as well as candidate genes for the Ciz1 KO phenotype. For 
this reason, the q-value was again not considered for the selection of candidate 
genes. In agreement with the opinion of bioinformatics experts another layer of 
analysis was carried out, using the gene set enrichment analysis software (GSEA), 
described below.  
All RNA sequencing output data files are safely stored in the Coverley lab and are 
available upon request.  
 
2.5.6 Gene set enrichment analysis (GSEA) 
	
Gene enrichment analysis was done using the Gene Set Enrichment Analysis 
(GSEA) computational method (Subramanian et al, 2005) (Mootha et al, 2003). This 
software allows to compare a set of predefined genes from your own analysis, in this 
case the list of genes with a significant p-value (p<0.05) from the whole-genome 
analysis, with another set of genes which have been grouped together due to different 
criteria such as being involved in the same biological pathway, disease or 
chromosomal location for example. These annotated gene sets are collected in the 
Molecular Signatures Database (MSigDB). An example of a GSEA output together 
with a definition of each of the terms is shown in Table 2.8.  
 
Table 2.8. Example of GSEA analysis result. Each of the terms included in a typical GSEA output file 
has been defined. An example obtained from one of my GSEA analysis files has also been included.  
 
 
Column name Example Definition
Gene set name BMI1_DN.V1_UP Name given to a specific gene 
collection from the MSigDB
Description Genes up-regulated in DAOY cells 
(medulloblastoma) upon knockdown of BMI1 [Gene 
ID=648] gene by RNAi.
Description of the criteria used to 
define a particular gene set
Genes in gene set 147 Indicates the total number of genes 
that appear in a specific gene 
collection as defined by the MSigDB
Genes in overlap 37 Indicates the number of genes from 
the submitted list that overlap with 
the annotated gene set from the 
MSigDB.
p-value p = 2.67E-30 Statistical significance of the 
enrichment score for a single gene 
set
q-value q = 5.05E-28 The FDR corrected p-value used for 
multiple hypothesis testing. Indicates 
likelihood that the reported p-value is 
a false positive (when q>0.05)
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2.5.7 Heatmaps 
	
Heatmaps were generated using R software (R Core Team, 2016) using the RStudio 
platform (RStudio Team, 2015) and the library gplots package (Warnes et al, 2016) 
with the hetmap.2 function. For heatmaps showing FPKM values, RColorBrewer 
(Neuwirth, 2014) was used to generate the orange-red colour palette.  
 
2.6 Immunofluorescence 
	
Cells were grown on glass coverslips and then briefly exposed to 0.1% Triton X-100 
in PBS, fixed with 4% paraformaldehyde (PFA), rinsed twice with PBS, and then 
blocked using an antibody buffer (10mg/ml nuclease and protease free bovine serum 
albumin (BSA, Jackson, Cat:001-000-162), 0.02% w/v SDS, 0.1% v/v Triton X-100 in 
PBS). Primary antibody was added to the coverslip at the indicated concentration 
(Table 2.9) and diluted in antibody buffer, followed by incubation in a humidified 
chamber at 37°C for a period of 2 hours. Following wash with antibody buffer to get 
rid of excess primary antibody, the secondary antibody was added to the coverslip at 
the indicated concentration (Table 2.9) and incubated for 1 hour at 37°C.  
2.6.1 Antibodies 
 
 
Table 2.9. Summary of antibodies used for immunofluorescence. 
 
CIZ1 antibodies
Antibody Origin Concentration Secondary antibody Concentration
1794 Rabbit polyclonal 1:2000 Alexa Fluor 488 green 
goat a-rabbit /Alexa 
Fluor 568 red goat a-
rabbit 
1:1000
1:2000
Nov4 
(ABIN261701, Novus 
Biologicals)
Rabbit polyclonal 1:500 Alexa Fluor 568 red 
goat a-rabbit 
1:1000
1:5000
Other antibodies
H3K27Me3 
(ab6002, Abcam) 
Mouse monoclonal 1:2000 Alexa Fluor 568 red 
goat a-mouse
1:2000
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Figure 2.2. Schematic of binding epitopes of CIZ1 antibodies 1794 and Nov4.  
 
2.6.2 Imaging 
	
Imaging was done using a Zeiss Axiovert microscope with a x63/1,40 oil immersion 
objective. Data was collected using an AxioCam camera and Openlab software. 
Images were manipulated using Adobe Photoshop CS4 to enhance fluorescence for 
printing purposes. In cases where levels of fluorescence are relevant for interpretation 
of the results all images were equally manipulated (as indicated in figures).  
 
2.7 Nuclear matrix extraction 
	
Before immunofluorescence detection with H3K27me3 antibody coverslips were 
subjected to nuclear matrix extraction to maximize access of the antibody to the 
methylation mark. The reagents required for this extraction, kindly provided by PhD 
student Emma Stewart, are indicated below:   
 
- Cytoskeletal buffer (CSK) with 0.1% Triton-X-100 (Table 2.10) in DEPC water. 
- CSK DS (CSK with Triton ad indicated above and 0.5M NaCl) 
- 1x DNase buffer (40mM Tris/HCl, 10mM NaCl, 6mM MgCl2, 1mM CaCl2, pH 
7.9) 
- PBS in DEPC water 
- 8% paraformaldehyde (PFA) 
- 5M NaCl in DEPC water 
- 10% TX100 in DEPC water 
- DNase (Roche, Cat. No. 04716728001) used at a concentration of 1:50 during 
a 15-minute incubation time.  
2     3     4     5           6      7                 8                          9          10         11     12    13       14 15    16      17
Nov4179417941794
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Table 2.10. List of components of CSK buffer 
 
Cells grown on coverslips were then subjected to nuclear matrix protocol, as indicated 
in Figure 2.3. Cells on coverslips were immersed in CSK buffer, followed by CSK 
buffer with detergent and then after immersion in DNase buffer treated with DNase at 
37°C for 15 minutes.  Cells were then washed in CSK-DS buffer and then fixed in 8% 
PFA for a period of 20 minutes. After washing in PBS cells were then subjected to 
standard immunofluorescence protocol.  
 
Figure 2.3. Schematic of nuclear matrix extraction protocol.  
 
 
2.8 Plasmid DNA transfection 
	
Cells on coverslips were grown to 80% confluence prior to transfection on 24-well 
plates. Cells were then transfected with approximately 0.5μg of the chosen GFP-
tagged Ciz1 DNA construct (Table 2.11) together with 50μl of Opti-MEM I Reduced-
Serum Medium (Cat. No.31985) and 1.5μl of the transfection reagent TransIT-LT1 
Reagent (Cat. No. MIR2300).  
	
Reagent  Quantity (for 
50mL) 
Final 
concentration 
PIPES/KOH (1M, 
pH 6.8)  
0.5 mL 10mM  
NaCl (5M)  1 mL 100mM  
Sucrose 5.135 g 300mM  
EGTA (250mM) 0.2 mL 1mM  
MgCl2 (1M)  50 µl  1mM  
DTT (1M) 50 µl  1mM  
Protease inhibitor 
cocktail 
1 tablet - 
CSK CSK-DS
DNase 
buffer
DNase 
(15 min)
Cells on 
coverslips
IF
PBS-
DEPC
CSK-
DS
8% PFA
(20 
min)
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Construct Origin Amino acids 
present 
Total fragment 
size (aa) 
Provided by 
Full-length GFP-
CIZ1 
Mouse Met1-845 
 
845aa Ainscough, J. 
GFP-C275 CIZ1 Mouse 570-845 275 Ainscough, J. 
GFP-I122 CIZ1 Mouse 708-830 122 Ainscough, J. 
GFP-N572 CIZ1 Mouse Met1-572 572 Ainscough, J. 
Full-length GFP 
eCIZ1 
Mouse CIZ1 D exons 2,6,8 
(Met84-196^202-342^391-
845) 
708 Ainscough, J. 
GFP-N572 eCIZ1 Mouse  (Met84-196^202-
342^391-572) 
435 Ainscough, J. 
Full-length GFP-
CIZ1 
Human Full-length CIZ1 (898aa) 898 Higgins, G. 
b-variant GFP-
CIZ1 
Human Full-length CIZ1 (D 
VEEELCKQ, exon 14) 
890 Higgins, G. 
F-variant GFP-
CIZ1 
Human Full-length CIZ1 D exons 
9-11, D part of exons 8 
and 12 
315 Swarts, D. 
Table 2.11. Summary table of mouse and human constructs used for transfection. Table has been 
adapted from Table 1 in Ainscough 2007. Numbers refer to amino acids (aa) at fragment boundaries, 
relative to full- length Ciz1 (Accession number NP_082688). In all ECiz1-derived fragments residues 1-
83 (exon 2), 197-201 (exon 6) and 343-390 (exon 8) are absent and indicated by chevrons. The total 
number of residues in each fragment is also indicated. 
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CHAPTER 3. IMPORTANCE OF CIZ1 DOMAINS FOR 
ITS TARGETING TO THE INACTIVE X  
 
3.1 Introduction 
 
The N-terminal part of the CIZ1 protein is required for its function in DNA replication 
(Coverley et al, 2005), while its C-terminal domain is important for binding to the 
nuclear matrix (Ainscough et al, 2007). However, the importance of these two 
domains in the targeting and binding of CIZ1 to the inactive X chromosome remains 
uninvestigated. Some of the motifs within the protein include three zinc fingers, an 
acidic domain and a matrin 3 domain (Figure 3.1). Matrins are a set of highly 
conserved proteins which are localized to the nuclear matrix. The matrin 3 domain 
(MH3), contains a matrin 3 type zinc finger (Belgrader et al, 1991) (Figure 3.1). Also 
indicated below are the fragments that are spliced out in a mouse embryonic Ciz1 
splice variant (eCIZ1), which will be of interest in this chapter, and which lack parts of 
exons 2, 6 and 8 (Coverley et al, 2005). 
	
Figure 3.1. Schematic of full-length CIZ1 mouse protein. Indicated in purple are the sequences, 
which are spliced out in eCIZ1 variant. Indicated in blue are the three zinc fingers within the protein; in 
red, the acidic domain and in yellow the matrin 3 (MH3) domain within the C-terminus. The red arrow 
indicates the end of the region that spans the N572 construct.  
The use of CIZ1 specific antibody 1794 against endogenous CIZ1 and RNA FISH 
against the long non-coding RNA Xist have shown that in fact both entities colocalise 
in the nucleus. Since Xist can be used as a marker for the location of the inactive X 
chromosome this demonstrates that CIZ1 does in fact form high-density patches at 
the Xi, which in turn also colocalise with the Barr body (Ridings-Figueroa, 
unpublished).  
	
3.2 Aims 
The aim in this chapter is to investigate which domains of CIZ1 are required for: 
i) Transport of CIZ1 to the inactive X region. 
ii) Binding and accumulation of CIZ1 at the inactive X region. 
ZF ZF ZF AD MH3 2 6 8 
MFNPQL….SLQGLH  EPQVPS...QAHPQV  DSSSQ		
DNA replication domain (RD)	 Nuclear matrix attachment domain (AD) 
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3.3 Experimental design 
	
A set of already existing mouse and human GFP-tagged CIZ1 constructs of different 
lengths were transfected into wild-type female murine cells (3T3) in order to investigate 
their ability to form high-density patches at the Xi (Ainscough et al, 2007). Scoring was 
based on two parameters: i) ability of the expressed fragment to form discrete sub-nuclear 
patches at the Xi, ii) ability to interfere with accumulation of endogenous CIZ1 at the Xi.  
 
3.4 Results 
	
3.4.1 Full-length GFP-CIZ1 forms high-density patches at the Xi 
with high efficiency 
	
Previous work has shown that endogenous full-length CIZ1 accumulates at the 
inactive X chromosome forming high-density patches (Ridings-Figueroa, 
unpublished). The aim of this experiment is to introduce a positive control showing 
that full-length mouse GFP-CIZ1 (FL-CIZ1), like endogenous CIZ1, can form high-
density patches with high efficiency that colocalise with the Barr body and therefore 
mark the inactive X chromosome (Xi) (Figure 3.2). In fact, in approximately 81% of 
successfully transfected cells (Figure 3.2A) highly visible patches were scored. Three 
independent experiments were carried out, where n=100 for each biological replicate.  
 
A) Full-length GFP-CIZ1 
 
B) 
 
Figure 3.2A. Summary of transfection of full-length mouse GFP-CIZ1. Schematic of the full-length 
GFP-CIZ1 construct. Green structure represents the GFP tag. Figure 3.2 B. Full-length CIZ1 forms 
high-density CIZ1 patches at the inactive X. Transfection of GFP-tagged full-length CIZ1 into wild-
type 3T3 cells leads to formation of CIZ1 high-density patches at the Xi. Image on the far-right shows 
DAPI FL GFP-CIZ1 81%
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zoom in of GFP-CIZ1 positive cell. DNA was stained with DAPI (blue). White arrows indicate location of 
high-density CIZ1 patches at the inactive X chromosome. Number on the top right hand-side corner 
indicates the percentage of transfected cells with observed GFP-positive CIZ1 patches at the inactive X 
chromosome, obtained from the average of three separate experiments (biological replicates) where 
n=100 for each replicate.   Scale bars represent 10μm. 
3.4.2 C-terminus analysis shows binding at the Xi 
	
3.4.2.1 The C-terminal end of CIZ1 contains the sequences 
required for accumulation of CIZ1 at the Xi 
	
When transfecting the C-terminal end fragment (C275) into wild-type 3T3 mouse 
cells, CIZ1 high-density patches can be observed at the Xi (Figure 3.3B), although at 
very low frequencies, 14%, compared to full-length CIZ1 (Figure 3.3C). To confirm 
that the observed CIZ1 patches are in fact at the inactive X chromosome region, 
endogenous CIZ1 was stained with anti-CIZ1 1794 (see Methods, Figure 2.2). The 
1794 polyclonal antibody binds to the N-terminal end of CIZ1 and therefore does not 
bind to the expressed construct. Since previous evidence has shown that 
endogenous CIZ1 localises to the inactive X, staining endogenous CIZ1 introduces a 
control for the real location of the inactive X chromosome. Co-localisation between 
the GFP-C275 high-density patches and 1794 CIZ1 patches confirmed the ability of 
the C-term to accumulate at Xi region. The ability of the GFP-C275 construct to 
interfere with recruitment of endogenous CIZ1 to the Xi was also investigated (Figure 
3.3A). The ability of the 1794 antibody to bind endogenous CIZ1 at the Xi was not 
significantly different between transfected and non-transfected cells, suggesting there 
is no interference between the C275 construct and endogenous CIZ1 (Figure 3.3D).  
 
A shorter version of the C275 construct, the ‘internal’ I122 construct, containing amino 
acids 708-830 of the C-terminal end of full-length CIZ1 was transfected into wild-type 
3T3 cells and endogenous CIZ1 was stained using 1794 anti-CIZ1 antibody (Figure 
3.4). This experiment was only performed in one occasion, and only one I122 CIZ1 
high-density patch was observed at the Xi. This patch co-localised with endogenous 
CIZ1 patch at the Xi, suggesting the result is real. However, to confirm the validity of 
this finding, further repetitions of this experiment will be necessary in the future.  
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3.4.2.2 Investigating dependence of the C-terminus construct on 
endogenous CIZ1 to accumulate at the Xi 
	
To test whether the ability of the C-terminus construct to bind at the Xi is dependent 
on the presence of endogenous CIZ1, GFP-C275 construct was transfected into 
e13.17 Ciz1 KO cells (Ainscough, unpublished). No C275 high-density patches were 
observed (Figure 3.5) (n=200, two technical replicates), suggesting that in wild-type 
cells this construct has been dependent, either directly or indirectly, on endogenous 
CIZ1 to bind at the Xi. It is possible to argue that the 3T3 fibroblast cell line and the 
e13.17 Ciz1 KO PEF cell line are not directly comparable and for this reason, a 
summer student transfected the GFP-C275 construct into e13.1 wild-type female 
primary embryonic fibroblasts and observed that the construct is also able to form 
high-density patches at the Xi in this cell line as well as confirmed its inability to do 
the same in the e13.17 Ciz1 KO cell line (Cecere, personal communication).  
 
A) GFP-C275 CIZ1 
 
B) 
Competitive assay 
% Transfected cells with 1794 X patches 
 
% Non-transfected cells with 1794 X patches 
 
 
C) 
	
	
DAPI 1794 GFP-C275 CIZ1 14%
90% 96% 
	
	
	
	
	
	
37	
D)       E) 
	
Figure 3.3A.  Summary of transfection of mouse C275 GFP-CIZ1. Schematic of the CIZ1 GFP-C275 
construct indicates regions present (grey) and absent (white) from this construct. Figure 3.3B. Pie charts 
show the percentage of cells transfected with C275 GFP-CIZ1 construct that show 1794 patches at the 
Xi compared to the percentage of non-transfected cells with 1794 patches at the Xi. Figure 3.3C. The 
C-terminal fragment of CIZ1 contains the sequences required for binding at the Xi. Transfection of 
the GFP-tagged C275 (green) terminal fragment of CIZ1 into wild-type 3T3 cells shows that this construct 
can bind at the Xi region. Endogenous CIZ1 was stained using anti-CIZ1 1794 antibody (red). 
Colocalisation of the GFP high-density patch with the 1794 high-density patch, shows localization of the 
GFP construct at the Xi. DNA was stained with DAPI (blue). White arrows indicate location of high-
density CIZ1 patches at the inactive X chromosome. Number on the top right hand-side corner indicates 
the percentage of transfected cells with observed GFP-positive CIZ1 patches at the inactive X 
chromosome. The percentage is the average obtained from three separate experiments (biological 
replicates) where n=100 cells for each replicate. Scale bars represent 10μm.  Figure 3.3D. Efficiency 
of CIZ1 high-density patch formation at the inactive X chromosome. Transfection of full-length GFP-
tagged CIZ1 leads to formation of CIZ1 high-density patches at a significantly higher efficiency compared 
to transfection of GFP-C275 CIZ1 construct (F=0.07, t=4.69951E-05, p<0.001). *** used to indicate 
p<0.001. Error bars represent standard error of the mean from three independent experiments. Figure 
3.3E. Efficiency of endogenous CIZ1 detection with 1794 antibody in C275 transfected versus 
non-transfected cells. Transfection of GFP-C275 CIZ1 construct into wild-type 3T3 does not cause 
interference with the presence of endogenous CIZ1 at the inactive X.  Numbers are obtained from the 
average of two biological replicates where total n= 113 for transfected cells and n= 110 for non-
transfected cells. Error bars represent standard error of the mean of two independent experiments.  
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A) GFP-I122 CIZ1 (708-830) 
 
B) 
	
Figure 3.4A. Schematic of the ‘internal’ 122 GFP-tagged CIZ1 construct. Schematic of the construct, 
which contains 122 amino acids from the C-terminus end of CIZ1, indicates regions present (grey) and 
absent (white) from this construct. Figure 3.4B. The GFP-tagged I22 CIZ1 fragment contains the 
sequences required for binding at the inactive X region. Transfection of I122 GFP-CIZ1 construct 
into wild-type 3T3 cells shows binding at the inactive X region. Endogenous CIZ1 is stained using anti-
CIZ1 1794 antibody. White arrows indicate location of high-density CIZ1 patches at the inactive X 
chromosome. DNA was stained with DAPI (blue). Scale bars represent 10μm. This experiment was only 
performed once.  
 
A) GFP-C275 CIZ1 
 
B) 
	
Figure 3.5A.  Summary of transfection of mouse C275 GFP-CIZ1 in Ciz1 KO cells. A schematic of 
the CIZ1 GFP-C275 construct indicates regions present (grey) and absent (white) from this construct. 
Figure 3.5B. The C275 fragment of CIZ1 fails to form CIZ1 high-density patches in the absence of 
endogenous CIZ1. Transfection of the GFP-tagged C275 terminal fragment of CIZ1 (green) into e13.17 
Ciz1 KO cells shows failure of the construct to form patches at the inactive X chromosome in a Ciz1 KO 
context. DNA is stained with DAPI (blue). Number on the top right hand-side corner indicates the 
percentage of transfected cells with observed GFP-positive CIZ1 patches at the inactive X chromosome 
in Ciz1 KO cells. The percentage represents the average obtained from two separate experiments 
(biological replicates) where n=100 cells for each replicate. Scale bars represent 10μm.   
DAPI GFP-C275 CIZ1 0%
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3.4.3 N-terminus analysis shows dominant negative effect on 
endogenous CIZ1 
 
3.4.3.1 N572 GFP-CIZ1 is unable to form high-density patches at 
the Xi but interferes with the presence of endogenous CIZ1 at 
the Xi 
	
Following analysis of possible functions of the C-terminus end of CIZ1 in the binding 
of CIZ1 at the Xi I proceeded to analyse possible functions of the N-terminal end of 
the protein. When transfecting an N-terminal fragment, the N572 construct, into 3T3 
cells, no high-density CIZ1 patches are observed at the Xi region (Figure 3.6A) 
(Figure 3.6B). Location of the inactive X chromosome was determined by staining 
endogenous CIZ1 with Nov4 antibody, which binds the C-terminal end of the protein 
and therefore does not bind to the expressed fragment (see Methods, Figure 2.2). 
Interestingly it was observed that in non-transfected cells (Figure 3.6C) 72% of cells 
showed Nov4 X patches, compared to transfected cells where only a 31% had 
observable endogenous CIZ1 patches (Figure 3.6A). This significant drop suggests 
that transfection of the N572 construct interferes with the mechanism that allows 
endogenous CIZ1 to accumulate at the Xi patch. The reason why interference does 
not occur in 100% of cells remains unclear.  
 
3.4.3.2 The GFP-eCIZ1 variant of N572 construct lacks the 
sequences involved in the interference mechanism 
	
Alternatively spliced embryonic CIZ1 (eCIZ1) (Coverley et al, 2005) is missing 
sequences from exon 2, 6 and 8, which are present in full-length CIZ1. Since 
important functions have been linked to some of these sequences, eCIZ1 was picked 
as a good candidate for transfection into wild-type 3T3 cells. This will allow me to 
determine whether any of these sequences, also contained within the N-terminal end 
of the protein, could have important functions in the interference previously observed. 
I initially determined whether full-length eCIZ1 can form high-density patches at the 
Xi. Results showed that the construct can form CIZ1 high-density patches but at a 
low frequency of 15% (Figure 3.7A) (Figure 3.7B), significantly different to full-length 
CIZ1 (Figure 3.7E), but comparable to the percentage obtained when transfecting the 
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C275 fragment, which is also contained within eCIZ1 variant. This suggests that 
eCIZ1 does have the sequences required for binding at the inactive X region but could 
be missing sequences required for efficient targeting.  
 
A shorter version of eCIZ1, eN572, (Figure 3.7C) missing the C-terminal end of eCIZ1 
(C275) was also transfected into 3T3 cells and endogenous CIZ1 was stained using 
Nov4 antibody (Figure 3.7D). The aim of this experiment is to test whether this 
construct also shows the interference reported with the full-length version of N572. 
Results show that in fact, there is no significant difference between the number of 
cells with Nov4 X patches in transfected and non-transfected cells (Figure 3.7F), and 
therefore there is no interference with endogenous CIZ1. This implicates the 
sequences that are spliced out of eCIZ1 in the interference. 
 
A) GFP-N572 CIZ1 
 
B) 
Competitive assay 
% Transfected cells with Nov4 X patches 
 
 
% Non-transfected cells with Nov4 X 
patches 
 
 
 
C) 
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D) 
	
Figure 3.6A. Schematic of N572 mouse GFP-CIZ1. A schematic of the CIZ1 GFP-N572 construct 
indicates the regions which are present (grey) and absent (white) from the construct. Figure 3.6B. 
Competition assay. Pie charts reflect the ability of the construct to interfere with recruitment of 
endogenous CIZ1 at the Xi in transfected and non-transfected cells. Percentages are obtained from the 
average of three biological replicates, where total n=226 for transfected cells and n= 307 for non-
transfected cells.  Figure 3.6C. The N-terminal fragment of CIZ1 lacks sequences required for 
formation of CIZ1 high-density patches at the Xi and interferes with the presence of endogenous 
CIZ11 at the site. Transfection of a GFP-tagged N572 fragment (green) into wild-type 3T3 cells shows 
inability of this construct to form high-density patches at the inactive X region. Number on the top right 
hand-side corner indicates the percentage of transfected cells with observed GFP-positive CIZ1 patches 
at the inactive X chromosome in wild-type 3T3 cells. The percentage represents the average obtained 
from three separate experiments (biological replicates) where n1=100 cells, n2= 65 cells, n3= 61 cells.  
Endogenous CIZ1 (red) fails to accumulate at the Xi in N572 transfected cells. Scale bars represent 
10μm. Figure 3.6D. Endogenous CIZ1 high-density patches form at the Xi in non-transfected cells. 
Endogenous CIZ1 (red) accumulates at the inactive X in non-transfected cells. White arrows indicate 
location of high-density endogenous CIZ1 patches at the inactive X chromosome. Endogenous CIZ1 is 
detected with Nov4 antibody which also binds antigens external to the cell, leading to formation of a 
characteristic ‘antibody cap’ (indicated with yellow arrow). Scale bars represent 10μm. 
A) Full-length GFP eCIZ1 (D exons 2,6,8) 
 
B) 
 
 
 
C) GFP-N572 eCIZ1 (D exons 2,6,8) 
 
DAPI Nov4 GFP-N572 CIZ1
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D) 
Competitive assay 
% Transfected cells with Nov4 X patches 
 
% Non-transfected cells with Nov4 X 
patches 
 
 
E) 
 
 
F) 
 
G) 
 
Figure 3.7A. Schematic of full-length eCIZ1 variant. A schematic of the full-length eCIZ1 variant 
(which is missing fragments from exon 2,6 and 8, crossed regions) construct indicates regions present 
(grey) and absent (white) from this construct. Figure 3.7B. Full-length eCIZ1 variant forms high-
density CIZ1 patches at the Xi with low frequency. Transfection of full-length eCIZ1 (green) variant 
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into 3T3 wild-type cells shows ability of the construct to form patches at the inactive X region. DNA was 
stained with DAPI (blue). White arrows indicate location of high-density CIZ1 patches at the inactive X 
chromosome. Number on the top right-hand side corner indicates the percentage of transfected cells 
with observed GFP-eCIZ1 patches at the inactive X chromosome in wild-type 3T3 cells. The percentage 
represents the average obtained from three separate experiments (biological replicates) where n=100 
for each replicate.  Scale bars represent 10μm. Figure 3.7C. Schematic of N572 mouse GFP-eCIZ1 
variant construct. A schematic of the eCIZ1 variant (which is missing fragments from exon 2,6 and 8) 
GFP-N572 construct indicates regions present (grey) and absent (white) from this construct. Figure 
3.7D. Competitive assay. Table shows the results of the competition assay, where pie charts represent 
the percentage of cells that show endogenous CIZ1 patches at the Xi, both in transfected and non-
transfected cells. The percentage represents the average obtained from three separate experiments 
(biological replicates) where n=100 for each replicate. Figure 3.7E. The N-terminal fragment of eCIZ1 
variant fails to form high-density patches at the Xi. Transfection of the N572 fragment of eCIZ1 
(green) into wild-type 3T3 cells shows inability of the construct to form CIZ1 patches at the inactive X 
region. Number on the top right-hand side corner shows the percentage of transfected cells with 
observed GFP-eCIZ1 patches at the inactive X chromosome in wild-type 3T3 cells. The percentage 
represents the average obtained from three separate experiments (biological replicates) where n=100 
for each replicate.  Endogenous CIZ1 (red) is stained using anti-CIZ1 Nov4 antibody. DNA was stained 
with DAPI (blue). White arrow indicates location of high-density endogenous Nov4 CIZ1 patches at the 
inactive X chromosome. Scale bars represent 10μm. Figure 3.7F. Efficiency of CIZ1 and eCIZ1 variant 
constructs to form CIZ1 patches at the Xi. Transfection of full-length CIZ1 as well as eCIZ1 variant 
leads to formation of CIZ1 patches at the inactive X chromosome. CIZ1 forms patches at a significantly 
higher efficiency compared to eCIZ1 variant (t=0.002, p<0.01). Transfection of the N-terminal end of 
CIZ1 as well as eCIZ1 variant shows inability of both constructs to form high-density patches at the Xi. 
Error bars represent standard error of the mean from three independent experiments.  ** used to indicate 
p<0.01. Figure 3.7G. Differential ability of CIZ1 and eCIZ1 N-terminus constructs to interfere with 
endogenous CIZ1. Wild-type 3T3 cells, transfected with GFP-N572 CIZ1 construct, show a significantly 
lower percentage of cells with 1794 endogenous CIZ1 at the inactive X compared to non-transfected 
cells (F=0.92, t=0.0035, p <0.01). The percentage of cells with 1794 endogenous CIZ1 high-density 
patches at the Xi is not significantly different between cells transfected with GFP-N572 eCIZ1 construct 
and non-transfected cells. Error bars represent standard error of the mean. ** used to indicate p<0.01.  
3.4.4 Transfection of human constructs 
	
3.4.4.1 CIZ1 b-variant does not display a significantly different 
ability to form high-density patches at the Xi compared to full-
length human CIZ1 
	
A human CIZ1 splice-variant, known as b-variant, has an in-frame deletion of eight 
amino acids (VEEELCKQ) from exon 14 (Higgins et al, 2012). This variant is of 
special interest since it has been defined as a circulating biomarker for lung cancer 
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(Higgins et al, 2012). When transfecting a GFP-tagged construct of this variant into 
wild-type female 3T3 mouse cells, approximately 91.5% of transfected cells (GFP 
positive) (Figure 3.8A) showed high-density GFP patches at the Xi (Figure 3.8B). This 
is not significantly different from the 91.3% of transfected cells that show CIZ1 high-
density patches at the Xi when transfecting full-length human CIZ1 (Figure 3.8A) 
(Figure 3.8B). This suggests that the sequences missing from this construct do not 
have any important functions in recruitment or binding at the Xi. 
 
3.4.4.2 F-variant CIZ1 is unable to form high-density CIZ1 patches 
at the inactive X 
	
F-variant is a CIZ1 splice variant in which all of exons 9 to 11 and part of exons 8 and 
12 are removed (Figure 3.9A) (Swarts et al, in preparation) (Rahman et al, 2007). 
This splice event leads to a frame shift, which generates a short alternative reading 
frame and a premature stop codon. Transfection of a GFP-tagged F-variant construct 
into wild-type 3T3 cells shows inability of the construct to form high-density patches 
at the inactive X chromosome (Figure 3.9B). While conserving exons 2 and 6, F-
variant is missing part of exon 8. This makes it an ideal candidate to test for 
competition with endogenous CIZ1. In an initial experiment no interference was 
observed. Although the number of endogenous CIZ1 patches in transfected cells is 
lower than in non-transfected cells the difference is much smaller than in other 
transfections where clear interference has been observed. This suggests that exon 8 
might be responsible for interference, however, repetitions of this experiment would 
be necessary to confirm the result. 
  
A) Full-length GFP-Human CIZ1 
 
b-variant human CIZ1 
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B) 
 
 
Figure 3.8A. Summary of transfection of full-length human GFP-CIZ1 and human b-variant. A 
schematic of the full-length human CIZ1 and b-variant human CIZ1 indicates regions present (grey) and 
absent (hatched region) from this construct.  Figure 3.8B. Full-length GFP-tagged human CIZ1 and 
human b-variant form high-density patches at the Xi. Upper images show transfection of full-length 
GFP-tagged human CIZ1 (green) into wild-type mouse 3T3 cells, which can form patches at the Xi. 
Number on the top right-hand side corner indicates the percentage of transfected cells with observed 
GFP-positive human CIZ1 patches at the inactive X chromosome in wild-type 3T3 mouse cells. The 
percentage represents the average obtained from three separate experiments (biological replicates) 
where n=100 cells for each replicate. Bottom images show transfection of human b-variant CIZ1 (green) 
into wild-type 3T3 mouse cells and formation of GFP high-density patches at the Xi. DNA was stained 
with DAPI (blue). White arrows indicate location of high-density CIZ1 patches at the inactive X 
chromosome. Number on the top right-hand side corner indicates the percentage of transfected cells 
with observed GFP-positive human CIZ1 patches at the inactive X chromosome in wild-type 3T3 mouse 
cells. The percentage represents the average obtained from two separate experiments (biological 
replicates) where n=100 cells for each replicate. Scale bars represent 10μm. 
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C) 
 
Table 3.9A. Summary of transfections of human GFP-F-variant into wild-type 3T3 mouse cells. A 
schematic of the GFP-F-variant CIZ1 construct indicates regions which are present (grey) and absent 
(white) in this construct. Red region indicates the region of the protein generated because of the 
premature stop codon. Figure 3.9B. Competition assay. Table shows the results of the competition 
assay using pie charts which reflect the percentage of transfected and non-transfected cells with 
endogenous CIZ1 patches at the Xi. Figure 3.9C. GFP-tagged human CIZ1 F-variant fails to form 
high-density patches at the Xi. Transfection of GFP-tagged CIZ1 F-variant (green) into wild-type 3T3 
cells shows inability of the construct to form high-density patches at the Xi region. DNA was stained 
using DAPI (blue). Number on the top right-hand side corner indicates the percentage of transfected 
cells with observed GFP positive CIZ1 patches at the inactive X chromosome. Scale bars represent 
10μm. 
 
3.5 Discussion 
	
The ability of the C275 construct to form high-density patches at the Xi suggests that 
it contains the sequences required for stable binding of CIZ1 to the Xi (Figure 3.10). 
However, the low frequency could suggest that it lacks the sequences for efficient 
targeting to the site, only accumulating passively or by a less efficient delivery process 
than full-length CIZ1. It is also possible that the construct can efficiently bind but not 
stabilize at the site. To test this hypothesis, it would be possible to transfect the 
construct for varying periods of time and ask whether the percentage of cells with 
Ciz1 high-density patches decreases with time.  The number of full-length CIZ1 and 
C275 transfected cells does not appear to be different, just the number of transfected 
cells with high-density CIZ1 patches at the Xi, suggesting there is no difference in the 
speed of expression of these constructs.  The C275 construct contains two important 
functional domains, which could be responsible for the binding function: the acidic 
domain, within exon 14, and the MH3 domain, which spans part of exon 15 and 16. 
The acidic domain has been suggested to have a function in protein interactions 
(Mitsui et al, 1999). Although of unknown function, the MH3 domain (Belgrader et al, 
1991) has been suggested to allow binding of CIZ1 to DNA (Mitsui et al, 1999) 
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(Warder and Keherley, 2003) or the nuclear matrix (Ainscough et al, 2007). In 
addition, the zinc finger spanning amino acids 626 to 660, referred to as JAZ ds-RNA-
binding zinc finger protein, has been predicted to contain sequences, which may 
function in binding of double-stranded RNA (InterPro, [Accessed 11th June 2016).   
 
The ‘internal’ I122 construct, which spans the MH3 domain but lacks the acidic 
domain, is also able to form high-density patches at the Xi. Although at very low 
frequency, they are verified as Xi by colocalisation with endogenous CIZ1. This 
suggests that the MH3 domain is sufficient for stable recruitment of CIZ1 to the Xi. 
The significantly decreased efficiency suggests however, that other sequences 
contained within the C275 construct, and missing from the shorter I122 construct, 
contribute to stable binding. Due to time constraints, I was unable to obtain replicates 
of this experiment so to verify the result it would be necessary to repeat the 
experiment.  
 
Failure of the C275 construct to form high-density patches at the Xi in a Ciz1 KO 
context shows that binding is dependent, either directly or indirectly, on endogenous 
CIZ1. One possible hypothesis is that the construct is binding to CIZ1 itself. However, 
it is also possible that the construct is binding to an entity or structure that is either 
absent or disrupted in the absence of CIZ1. A likely candidate would be the long non-
coding RNA Xist, which becomes delocalised from the inactive X chromosome in the 
absence of CIZ1 (Ainscough et al, in preparation). This would likely cause ectopically 
expressed CIZ1 to also become delocalised.  
 
 
Figure 3.10. Schematic of CIZ1 regions implicated in transport and binding to the Xi. The N-
terminus region, and more specifically the regions contained within the N-terminus that are absent from 
eCIZ1 variant (indicated in purple), appear to be responsible for efficiently targeting to the Xi region, thus 
interfering with the presence of endogenous CIZ1 at the site. The C-terminus region, although unable to 
allow efficient targeting to the Xi, appears to be implicated in binding at the Xi.  
 
Regarding the N-terminus function of CIZ1, transfection of full-length embryonic CIZ1 
(eCIZ1) shows a significantly lower ability to form high-density patches at the Xi 
Binding at Xi region
Transport to Xi region
Putative regions involved in efficient transport to Xi 
and interference with endogenous CIZ1
N572	boundary MH3 domain
	
	
	
	
	
	
48	
compared to full-length CIZ1. In fact, the percentage of transfected cells with CIZ1 
high-density patches is very similar for both eCIZ1 variant and the C275 CIZ1 
construct. These observations suggest that it is eCIZ1 key functional domains, which 
contribute to efficient targeting (Figure 3.10). Since the C-terminal fragment is 
identical between CIZ1 and eCIZ1 variant this also suggests that those sequences 
are located at the N-terminus. We are the developing and testing the hypothesis that 
function encoded by the exons that are spliced out of eCIZ1 (2,4,8) support binding 
to an active transport mechanism that delivers CIZ1 to the Xi. This hypothesis is 
supported by the ability of the CIZ1 N572 fragment to interfere with the targeting of 
endogenous CIZ1. This dominant negative effect suggests that N572 could have the 
sequences required for transport to the Xi region, therefore displacing endogenous 
CIZ1.  Due to the lack of C-terminal sequences it would be unable to bind and form 
patches itself. This also provides further support that sequences contained within the 
C-terminus are the ones responsible for successful binding of CIZ1 at the Xi. Notably, 
transfection of the C-terminus construct does not cause any interference with the 
presence of endogenous CIZ1, controlling for the possibility that transfection itself is 
responsible for the dominant negative effect on endogenous CIZ1.   
 
Importantly, the N572 fragment of eCIZ1 (lacking parts of exon 2,6,8) does not cause 
interference with localization of endogenous CIZ1 at the Xi, further implicating these 
sequences in the dominant negative effect. The next step to determine what 
sequences of CIZ1 are required for successful recruitment to the Xi would be to 
investigate the functions of exon 2, the DSSQ fragment within exon 6 and the 
fragment of exon 8 missing from eCIZ1. All three sequences could be of potential 
importance. Exon 2 contains a glutamine-rich region. Although the function of these 
glutamine rich regions is still uncertain it is known that abnormal expansion of this 
residues has been linked with the generation of protein aggregations related to 
neurodegenerative conditions (Michelitsch et al, 2000). The DSSSQ fragment is 
identical between human and mouse protein and it has been reported that naturally 
expressed CIZ1 proteins can either contain or not this sequence, suggesting its 
presence or absence might be an important for the regulation of protein activity or 
function. Important functions have also been attributed to exon 8. A CIZ1 splice 
variant, which lacks a glutamine-rich region within exon 8, is overexpressed in 
patients with Alzheimer’s disease (Dahmcke et al, 2008).  
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Human CIZ1 b-variant is lacking eight amino acids from exon 14, which cause a one 
amino acid deletion from the acidic domain, and has been implicated in lung cancer.  
The ability of full-length human CIZ1 and b-variant to form high-density patches at the 
inactive X with a very similar efficiency suggests this domain might not have an 
important role in this process. In addition, the inability of F-variant CIZ1 to form CIZ1 
patches at the Xi, supports the hypothesis that the C-terminus, which is missing from 
F-variant is required for successful binding at the Xi region. In addition, the initial 
observation that F-variant does not interfere with recruitment of endogenous CIZ1 to 
the Xi suggests that exon 8, which is missing from this construct, could be responsible 
for this function. However, further repetition of the experiments as well as further 
investigation of exon 2 and 6 would be necessary to confirm this result. 
 
The results shown in this chapter begin to provide some information on a possible 
model that describes localisation and binding at the inactive X region. The N-terminal 
end, and most probably one or more of the sequences spliced out in eCIZ1 variant, 
could contain the sequences required for delivery to the X chromosome localisation. 
The C-terminus end of the protein on the other hand, contains sequences that are 
sufficient for binding of the protein at the inactive X, which is likely to occur through 
the MH3 domain. Possible new experiments would involve the generation of a series 
of constructs missing the fragments from exon 2, 6 and 8. These would then be tested 
either for their ability to form high-density patches at the same frequency as full-length 
CIZ1, or if missing the C-terminal domain, for their ability to interfere with the presence 
of endogenous CIZ1 at the inactive X region.  
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CHAPTER 4. ANALYSIS OF THE RELATIONSHIP 
BETWEEN CIZ1 AND H3K27ME3  
 
4.1 Introduction 
 
Methylation of histone 3 at lysine 27 (H3K27) is one of the events that occurs during 
X chromosome inactivation. This repressive mark, laid down by the PRC2 complex, 
contributes to maintenance of epigenetic silencing. An RNA FISH experiment 
targeting lnc-RNA Xist, one of the major players in X inactivation, showed that Xist 
becomes delocalized from the inactive X in a Ciz1 KO background unlike in a wild-
type scenario where Xist forms dense patches at the Xi. It is therefore of interest to 
assess whether other players such as the H3K27me3 mark are also affected by 
absence of CIZ1.  
 
4.2 Aims 
	
In this chapter I aim to investigate three main questions: 
 
- Test whether there is disruption of the H3K27me3 methylation mark from the 
inactive X chromosome in a Ciz1 KO background.  
- Using an inducible gene-expression system, test whether re-expression of 
Ciz1 in a KO context, is capable of reinstating the methylation mark and 
determine the kinetics.  
- In case of reinstatement of the methylation mark, test whether passage 
through the cell cycle is required.  
 
4.3 Experimental design 
	
These questions will be answered by using a Ciz1 KO and WT cell lines derived from 
PEFs, and the e13.17 Ciz1 KO cell line, which has a transgene capable of re-
expressing Ciz1 when doxycycline is added to the cell culture media (see Methods, 
Figure 2.1). By exposing the e13.17 KO cell line to doxycycline for different periods 
of time ranging from 6 to 48 hours, I will test the effects of exposure time on the 
reinstatement of the methylation mark at the Xi. In addition, thymidine will be used to 
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arrest cells at G1-S phase to allow me to investigate whether blocking passage 
through the cell cycle prevents or in any way affects, reinstatement of the H3K27 
methylation mark at the Xi.  
 
4.4 Results 
	
4.4.1 Ciz1 KO causes disruption of the H3K27me3 methylation mark at 
the Xi 
	
Detection of the H3K27 methylation mark in a WT and Ciz1 KO cell line by means of 
immunofluorescence, revealed loss of the methylation mark at the inactive X 
chromosome in the e13.15 Ciz1 KO cell line (Figure 4.1). As shown in Table 4.1, in 
the wild-type cell line approximately 98% of the cells have CIZ1 high-density patches 
at the Xi, and 97% of these show a H3K27 patch at the same location.  However, in 
Ciz1 null cells (e13.15 KO cell line) CIZ1 patches are absent from all cells and the 
H3K27 methylation mark is also lost from the Xi in 100% of cells.  
 
As seen in Figure 4.1, loss of CIZ1 in the KO cell line seems to not just disrupt the 
H3K27 methylation mark at the Xi but seems to lead to an overall decrease in the 
H3K27 staining across the nucleus. This observation suggests that loss of CIZ1 could 
have a much wider effect on the methylation mark than originally expected.  
 
	
Figure 4.1. Knockout of Ciz1 leads to disruption of the H3K27me3 methylation mark. Top images 
show immunofluorescence experiment on e13.1 WT PEF cells. CIZ1 high-density patches (green) at the 
Xi colocalise with H3K27me3 methylation mark patches (red) at the Xi. Bottom images show 
immunofluorescence experiment on e13.15 Ciz1 KO PEF cells. No CIZ1 (green) high-density patches 
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are observed at the Xi although some residual staining is observed in the nucleus. In the absence of 
CIZ1 the H3K27me3 mark (red) is lost from the Xi and decreased in the rest of the nucleus. White arrows 
indicate location of high-density CIZ1 patches and H3K27me3 patches at the inactive X chromosome, 
respectively. Scale bars represent 10μm.   
Immunofluorescence results Wild-type Ciz1 KO 
% cells with CIZ1 patches at the Xi 98% 0 
% cells with H3K27me3 patches at the 
Xi 
97% 0 
Table 4.1. Table showing differences in percentage of cells with H3K27me3 mark at the Xi in wild-
type versus Ciz1 KO cell lines. In dark grey, percentage of cells with CIZ1 patches at the Xi in wild-
type versus Ciz1 KO cells. In light grey, percentage of cells with H3K27me3 patches at the Xi in wild-
type versus Ciz1 KO cells. A total of 100 cells was counted for both the wild-type and Ciz1 KO cell lines.  
 
4.4.2 Re-expression of Ciz1 in a Ciz1 KO background leads to 
reinstatement of the methylation mark 
 
An important question to ask is whether re-expression of Ciz1 in a KO background 
can reverse the effects that the absence of CIZ1 has on the H3K27 methylation mark. 
By exposing the e13.17 Ciz1 KO cells, which contains a doxycycline inducible Ciz1 
transgene, to doxycycline during varying time points, ranging from 6 hours to 48 hours 
I was able to ask not only whether the methylation mark is reinstated at the inactive 
X chromosome, but also how long after re-expression of Ciz1.  
 
Results show that the methylation mark is in fact present following re-expression of 
Ciz1, and that, as the time of exposure to doxycycline is lengthened, the number of 
cells with observable CIZ1 high-density patches at the Xi increases, starting at 52% 
at 6h and then reaching a plateau at approximately 73% at 48h (Figure 4.3). The 
number of cells with H3K27me3 patches, which colocalise with the CIZ1 patches at 
the Xi (Figure 4.2), also increases with time although at a slower rate, going from 24% 
at 6 hours to 60% at 48 hours (Figure 4.3). This result suggests that re-expression of 
Ciz1 and recruitment of the protein to the Xi precedes reinstatement of the H3K27 
methylation mark.  
 
However, one important anomaly was observed in this experiment. Unlike for the 
e13.15 Ciz1 KO cells, where the H3K27me3 mark is lost from the Xi in 100% of cases, 
in the e13.17 Ciz1 KO cell line, which contains the Ciz1 transgene, 55% of cells 
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showed H3K27me3 mark at the Xi in the absence of doxycycline (Figure 4.3), that is 
in the absence of Ciz1 re-expression.  This could be explained if the Ciz1 transgene 
in the e13.17 cell line showed some leaky expression, however as shown later in this 
thesis, qPCR analysis shows there is no Ciz1 expression at 0 hours in the absence 
of doxycycline (Figure 5.2). Interestingly, the number of cells showing H3K27me3 
marks at the Xi dropped by more than half immediately following induction of Ciz1 
and then gradually increased again. This data does not fit the simple model suggested 
by previous data and implies a CIZ1-independent mechanism for deposition of the 
H3K27m3 mark at the Xi, which is switched off when Ciz1 is expressed. 
 
	
Figure 4.2. Immunofluorescence experiment showing presence of the H3K27me3 mark at the Xi 
following re-expression of Ciz1. Immunofluorescence experiment shows re-expression of CIZ1 
(green) and accumulation at the Xi following exposure to doxycycline for periods ranging from 6 to 48 
hours. The H3K27me3 mark (red) colocalises with the CIZ1 high-density patch at the Xi. White arrows 
indicate location of high-density CIZ1 patches and H3K27me3 patches at the inactive X chromosome.  
Scale bars represent 10μm.  
24h
48h
6h
12h
CIZ1 H3K27me3DAPI
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Figure 4.3. Histogram showing percentage of cells with CIZ1 and H3K27me3 density patches at 
the Xi following re-expression of Ciz1 in e13.17 Ciz1 KO cell line. In dark grey, percentage of cells 
with CIZ1 patches at the Xi. In light grey, percentage of cells with H3K27me3 patches at the Xi. The 
e13.17 Ciz1 KO cell lines was exposed to 10µg/mL of doxycycline for time points ranging from 6 to 48 
hours. A 0-hour time point, with no doxycycline, was also included. At 0 hours 0% of the cells showed 
CIZ1 patches at the Xi. Numbers of the 0-hour time point represent an average of two technical replicates 
with n=100 of each replicate. Numbers of the 6 and 12-hour time point represent an average of three 
technical replicates with n=100 of each replicate. Error bars represent standard error of the mean. 
Numbers of the 24 and 48-hour time point represent data from one single replicate with n=100.  
	
4.4.3 Reinstatement of the H3K27me3 mark is initially delayed in non-
cycling cells 
	
Another question of interest is whether reinstatement of the H3K27 methylation mark 
at the inactive X chromosome is dependent on progression through the cell cycle.  To 
address this question, the same experiment as above was repeated but in this 
occasion the cells were prevented from cycling by adding thymidine to the cell culture 
media.  Again, increasing exposure to doxycycline results in an increase of cells with 
CIZ1 patches at the inactive X (Figure 4.4), going from 55% at 6 hours to 70% at 48 
hours (Figure 4.5). These results do not differ from the minus thymidine experiment, 
suggesting that recruitment of CIZ1 to the Xi is not a cell cycle dependent 
phenomenon. Also, as seen previously, this is followed by reinstatement of the H3K27 
methylation mark at the Xi. However, in this occasion, the rate at which the 
methylation mark is laid down is significantly delayed compared to the minus 
thymidine experiment (Figure 4.5). At 6 hours, with thymidine, only 2% of cells show 
0
10
20
30
40
50
60
70
80
90
100
0h (no dox) 6h 12h 24h 48h
+ doxycycline / - thymidine
% cells with CIZ1 patches at the Xi % cells with H3K27me3 patches at the Xi 
	
	
	
	
	
	
55	
H3K27 methylation marks at the Xi, compared to 24% at the same time point without 
thymidine. Despite this initial delay, by the end of the time course, the total percentage 
of cells with H3K27me3 marks is not very different between the cycling, 60%, and 
non-cycling cells, 55%.  
 
 
Figure 4.4. Immunofluorescence experiment showing reinstatement of the H3K27me3 mark at the 
Xi following re-expression of CIZ1 in cell cycle arrested cells. Immunofluorescence experiment 
shows re-expression of CIZ1 (green) and accumulation at the Xi following exposure to doxycycline for 
periods ranging from 6 to 48 hours. The H3K27me3 mark (in red) colocalises with the CIZ1 high-density 
patch at the Xi.  White arrows indicate location of high-density CIZ1 patches and H3K27me3 patches at 
the inactive X chromosome. Scale bars represent 10μm.  
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Figure 4.5. Histograms showing reinstatement of the H3K27me3 mark following re-expression of 
CIZ1 in thymidine treated cells. In dark grey, percentage of cells with CIZ1 patches at the Xi. In light 
grey, percentage of cells with H3K27me3 patches at the Xi. The e13.17 Ciz1 KO cell lines was exposed 
to thymidine and then exposed to 10µg/mL of doxycycline for time points ranging from 6 to 48 hours. A 
0-hour time point, with no doxycycline, was also included. At 0 hours 0% of the cells showed CIZ1 
patches at the Xi. Numbers showed represent one replicate per time point with n= 100 cells for each 
time point.  
 
4.5 Discussion 
	
Experiments in this chapter have confirmed disruption of the H3K27me3 mark from 
the Xi in the absence of CIZ1 protein for one cell line, while in the transgene-
containing line the data is more complicated. Nevertheless, my results, together with 
previous evidence that loss of CIZ1 results in delocalization of Xist from the inactive 
X, argue that in the absence of CIZ1 important changes occur at the inactive X. Given 
the anomaly observed at the 0-hour time point in the CIZ1 re-induction experiment it 
is important to take into account that such drastic disruption of H3K27me3 signal from 
the Xi might not occur in all cell types. It is possible that in some cell types alternative 
pathways are in place that compensate for the absence of the protein. Given the fact 
that the H3K27me3 patches that are observed at the 0-hour time point disappear 
following induction of CIZ1 with doxycycline it is possible that this putative alternative 
pathway, is overridden by a CIZ1-dependent mechanism when expression of the 
protein is restored. However, this is just a possible hypothesis, and the mechanism 
for H3K27me3 at the Xi in the absence of CIZ1 will have to be further investigated. A 
possible approach would be to test for absence or presence of the H3K27me3 mark 
at the Xi in other Ciz1 KO cell lines, with no transgene, to see whether the methylation 
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mark is ever present in the total absence of CIZ1. This could be done through 
immunofluorescence as well as by looking at protein levels on a Western blot. These 
results could be compared to those obtained when analysing the e13.17 cell line with 
the transgene. Another possibility that must be considered is the fact that the growth 
media used to grow the cells could contain traces of tetracycline antibiotics which 
could be sufficient to induce re-expression of Ciz1 in the e13.17KO cell line and 
therefore responsible for the observed methylation mark at a 0h time point.   
 
In addition, loss of CIZ1 also seems to lead to a general reduction of H3K27me3 
signal in the rest of the nucleus, at least in the e13.15 Ciz1 KO cells. This unexpected 
result suggests that the impact that loss of CIZ1 protein has on the methylation mark 
might not be specific to the inactive X but that it might have a more widespread effect 
on the mechanism that allows deposition of the epigenetic mark by PRC2 elsewhere 
in the nucleus. However, it is crucial to confirm this observation by means of other 
experiments, such as for example, Western blot.  
 
Regarding the CIZ1 re-induction experiment, I have confirmed that expression of 
CIZ1 in a Ciz1 KO background is capable of reinstating the H3K27me3 mark at the 
Xi. This experiment argues that loss of the methylation mark is a CIZ1 specific 
phenomenon. Interestingly, blockage of the cell cycle does not affect formation of 
CIZ1 high-density patches at the Xi, suggesting that movement of CIZ1 to the site 
occurs through a mechanism that is independent of progression through the cell 
cycle. Blockage of the cell cycle does not prevent reinstatement of the H3K27 
methylation mark either but rather just delays it. This delay occurs between the 0 and 
6-hour time point, where the rate of H3K27me3 mark reinstatement is significantly 
higher in the non-arrested cells. This result could suggest that following re-expression 
of CIZ1 a CIZ1-dependent pathway comes into place in order to reinstate the 
H3K27me3. However, it is possible that this pathway is at the same time dependent 
on progression through the cell cycle, and since the cells have been arrested with 
thymidine, a second pathway, which is CIZ1- and cell-cycle-independent comes into 
place and allows fast reinstatement of the methylation mark. It is also possible that 
this is the same pathway that allows deposition of the mark at the 0-hour time point 
in the absence of CIZ1. Nevertheless, this is one of many other possible scenarios 
that could explain this phenomenon and further research will have to address this 
question in a more specific manner.  It is also of interest to investigate the reasons 
why the e13.15 Ciz1 KO cell line is able to grow and survive with a disrupted 
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H3K27me3, which is unusual, given the importance of this repressive epigenetic mark 
on basic processes such as cell proliferation and differentiation (Margueron and 
Reinberg, 2011). It is possible that in this cell line levels of the methylation mark have 
been dramatically reduced but are still sufficient to allow survival of the cell line so it 
would be interesting to compare the levels of protein by Western blot between the 
e13.15 cell line to those of a wild-type. It could also be of interest to test whether the 
e13.15 cell line shows any anomalies in cell proliferation or markers of differentiation.  
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CHAPTER 5. GENOME-WIDE EXPRESSION ANALYSIS  
	
5.1 Introduction 
	
Previous work has shown that loss of Ciz1 leads to changes at the inactive X, 
including delocalisation of Xist and disruption of the H3K27 methylation mark. 
However, whether these events lead to alterations at the level of gene expression 
from the Xi remains unknown. In addition, the effects that knockout of Ciz1 has on 
the rest of the genome are also not known.  
 
5.2 Aims 
	
The aims of this experiment are divided into two main sections involving i) analysis of 
gene expression from the X chromosome and ii) analysis of gene expression from 
the whole genome.  
 
• X chromosome analysis: 
- Obtain an overview of gene expression from the X chromosome in wild-type 
cells compared to Ciz1 knockout cells. 
- Determine whether there is any evidence of gene reactivation from the Xi as 
a consequence of loss of Ciz1. 
- Investigate whether, in the absence of Ciz1, expression from genes at the X 
inactivation centre is affected.  
 
• Whole-genome analysis 
- Investigate effects of Ciz1 KO on genes from the whole genome. 
- Identify potential gene sets that are significantly affected by Ciz1 KO  
- Investigate possible links between loss of Ciz1 and the female specific 
lymphoma-like phenotype observed in Ciz1 KO mice.  
 
5.3 Experimental design 
	
These questions will be addressed by means of a high-throughput RNA sequencing 
experiment, which involved the following steps (Figure 5.1): 
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• Extraction of RNA from a set of selected wild-type and Ciz1 KO cell lines (see 
below). 
• Analysis of integrity of the RNA samples. 
• Preparation of cDNA libraries for sequencing. 
• Sequencing by Illumina 3000 system.  
• Analysis of results by me with support from bioinformatics specialist in York 
Biology Technology Facility, Dr Peter Ashton and Dr. Richard Randle-Boggis.  
 
 
Figure 5.1 Schematic showing laboratory work-flow for the RNA sequencing experiment. 
 
5.4 Results 
	
5.4.1 Preliminary work for RNA sequencing analysis 
	
5.4.1.1 Selection of cell lines for RNA sequencing samples 
  
The main aim of the RNA sequencing experiment is to compare levels of gene 
expression between a wild-type and a Ciz1 knockout condition, using primary 
embryonic mouse female fibroblasts (PEFs). In order to obtain statistically significant 
results three different cell lines of each genotype where selected for the experiment 
(see Methods, Table 2.1). Each cell line within the wild type and knockout selection 
Culture of cell lines
RNA extraction and DNase treatment
Agilent 2100 Bioanalyzer (RNA integrity 
numbers (RIN)) 
cDNA libraries (NEBNext Poly(A) mRNA 
Magnetic Isolation Module)
Sequencing on a single lane of the Illumina 
3000 system
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is derived from a different mouse (cell lines generated by Dr. J Ainscough), which will 
allow accounting for biological differences in gene expression between individuals.  
 
In order to begin to address whether re-expression of Ciz1 (in a Ciz1 KO background) 
is able to reverse any effects on gene expression, the e13.17 Ciz1 KO cell line, which 
contains a doxycycline inducible Ciz1 transgene, was also included (see Methods, 
Figure 2.1). In addition, in order to account for any possible direct effects that 
doxycycline could have on gene expression, a normal Ciz1 KO cell line, e13.15, was 
also exposed to doxycycline and included in the RNAseq analysis (see Methods, 
Table 2.1).  
 
Another question of interest is whether there are any differences in gene expression 
from the X chromosome between female and male cell lines and whether these 
differences could help explain the female specific lymphoma-like phenotype. If results 
do not show that the lymphoma phenotype could be linked to X inactivation, other 
differences between female and male gene expression in the rest of the genome 
could also be of interest for the same reason.  In order to begin to investigate these 
questions, a single cell line each derived from a wild-type and a knockout male mouse 
were included in the samples for sequencing (see Methods, Table 2.1).  
 
Finally, it is also of interest to begin to assess whether the gene expression obtained 
in cultured cell lines does in any way compare to that in tissue samples obtained 
directly from the mice. For this reason, a tissue sample from the spleen of two female 
mice, one wild-type and one knockout, was also included. The knockout female 
mouse presented a lymphoma-like phenotype (see Methods), in which one of the 
affected organs is the spleen (Dr. Justin Ainscough, personal communication).  
 
In order to ensure minimal variability in gene expression levels due to differences in 
treatment of the cells all selected cell lines were plated and grown to 80% density and 
no further than passage number 4 before homogenization with TRIzol (see Methods). 
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5.4.1.2 Testing ability of the e13.17 KO cell line to express GFP-CIZ1 
upon induction with doxycycline 
	
A quantitative (real-time) PCR experiment was performed preliminary to the RNA 
sequencing experiment. One of the aims of this experiment is to confirm that addition 
of doxycycline to the media of e13.17 KO cells line does in fact result in expression 
of Ciz1. Although expression of GFP-CIZ1 has been previously confirmed by means 
of immunofluorescence experiments it is crucial to look at levels of expression. In 
addition, I will investigate the effect that different exposure times to doxycycline, 
ranging from six to seventy-two hours, has on relative levels of Ciz1 transcript, in 
order to determine the most appropriate time point for RNAseq analysis. Results of 
this experiment will also provide useful information on levels of Ciz1 expression in 
relation to Xist expression, in the same time frame.  
 
Results of the qPCR experiment show significant expression of Ciz1 in the e13.17 
KO cell line following addition of doxycycline, compared to the e13.17 KO cell line 
with no doxycycline, which shows no Ciz1 expression (Figure 5.2). This shows that 
the cell line is suitable for use in the RNA sequencing experiment. It is also important 
however to choose a time point, because financial constraints limited my RNAseq 
analysis to 12 samples in total. Levels of Ciz1 expression reach a peak at 24 hours, 
then decrease at 48, and then increase again at 72 hours (Figure 5.2). It is important 
to note the overwhelming levels of Ciz1 compared to wild-type levels (e14.4), over 90 
times higher at 24 hours, so when analysing the RNA sequencing data, it will be 
necessary to check whether the same phenomenon is observed. Levels of expression 
of Xist slightly decrease across the time course from 6 to 72 hours. However, the two 
controls with no dox at the beginning (0i) and end (0f) of the experiments do not 
remain constant, suggesting this decrease might be related to other factors such as 
for example, cell density. Although these might be interesting observations, results 
from the RNA sequencing experiment will provide further and more useful information 
on the levels of expression of Xist in the presence and absence of Ciz1 expression.   
Although there is an apparent drop at the 48-hour time point, I chose this for 
my RNA sequencing as it represents a time after induction at which all the cells in the 
analysis can be expected to have passed through at least one cell cycle, and so have 
implemented any nuclear organizational changes that might result from the presence 
of CIZ1. 
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Figure 5.2. Ciz1 is highly expressed following addition of doxycycline to the media of e13.17 Ciz1 
KO cells. Histogram showing levels of Ciz1 expression (dark grey) following induction with doxycycline 
compared to no expression of Ciz1 in un-induced controls (0i, 0f). Levels of Xist expression are indicated 
by light grey bars.  Levels of expression are expressed relative to wild-type levels, e14.4 WT, which was 
used as the calibrator. 	 
5.4.1.3 Investigating the effects of doxycycline concentration on induction 
of Ciz1 expression 
	
Doxycycline, which is a tetracycline antibiotic commonly used in inducible gene 
expression systems, has been previously reported to have off-target effects on gene 
expression and metabolism (Ahler et al, 2013).  For this reason, I tested a range of 
doxycycline concentrations on the e13.17 KO inducible cells, ranging from 0.5μg/mL 
to 10μg/mL. The aim of this experiment is to identify the lower concentration of 
doxycycline that can efficiently induce Ciz1 expression. Output was quantified based 
on the efficiency of formation of GFP-CIZ1 high-density patches at the inactive X, and 
was also scored for overall expression of GFP-CIZ1. 
 
A concentration of 10μg/mL of doxycycline achieved induction of Ciz1 expression in 
over 90% of the cells while 5μg/mL of doxycycline induced approximately 80% of the 
cells to express GFP-CIZ1 (Figure 5.3A). The percentage of GFP positive cells with 
correspondent GFP-CIZ1 high-density patches at the Xi however does not greatly 
differ between both concentrations (Figure 5.3B) (Figure 5.3C). For this reason, and 
to minimize possible direct side effects of doxycycline on gene expression the lower, 
sub-saturating, concentration of 5μg/mL was finally selected for use in the RNA 
samples for sequencing. 
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Figure 5.3A. Histograms showing ability of varying concentrations of doxycycline to induce 
expression of GFP-CIZ1 in e13.17 Ciz1 KO cells. The e13.17 Ciz1 KO cell line was exposed to 
concentrations of doxycycline varying from 0.5μg/mL to 10μg/mL and the percentage of GFP-CIZ1 
positive cells was assessed for each concentration. Data labels (n = x) indicate the total number of cells 
that was counted for each concentration. Figure 5.3B. Histograms showing ability of varying 
concentrations of doxycycline to induce expression of Ciz1 and formation of GFP-CIZ1 high-
density patches at the Xi in e13.17 Ciz1 KO cells. The e13.17 Ciz1 KO cell line was exposed to 
concentrations of doxycycline varying from 0.5μg/mL to 10μg/mL and the percentage of GFP-CIZ1 
positive cells with GFP-CIZ1 patches at the Xi was assessed for each concentration. Figure 5.3C. 
Example images of e13.17 Ciz1 KO cell lines after exposure to doxycycline. Top images show 
control experiment of e13.17 Ciz1 KO without doxycycline exposure. Middle and bottom images show 
e13.17 Ciz1 KO cell lines after being exposed to 5μg/mL and 10μg/mL of doxycycline, respectively. 
GFP-CIZ1 (green) is expressed following induction with doxycycline. DNA was stained with DAPI (blue). 
White arrows indicate GFP-CIZ1 patches at the inactive X. Scale bars represent 10μm. 
 
5.4.1.4 RNA integrity analysis 
 
Following RNA extraction and DNase treatment (see Methods), I checked the integrity 
of my DNase treated RNA samples by running an aliquot of the RNA samples on an 
agarose gel, stained with ethidium bromide (Figure 5.4). The presence of two clear 
bands, corresponding to the 28s and 18s rRNA bands, together with the absence of 
smears, indicates that the RNA is, in fact, intact. RNA samples were further analysed 
using a NanoDrop spectrophotometer in order to obtain the concentration of RNA 
(Figure 5.5) and the A260/280 values (Figure 5.4), which ideally should be as close 
to 2 as possible for pure RNA. All 12 samples showed good concentration and 
integrity values and were therefore transferred to the Genomics facility at University 
of York, where they were run through an Agilent 2100 Bioanalyzer (see Methods). 
RNA integrity numbers (RIN) (Sup. info) confirmed the quality of the samples and so 
the cDNA libraries were prepared and then sent for sequencing (see Methods).  
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Figure 5.4 Analysis of RNA integrity of RNA samples for sequencing. Top image shows RNA 
samples run on an agarose gel. Bands corresponding to the two ribosomic RNA bands are indicated. 
Order of the samples corresponds with the order indicated in the histogram below. Histograms show the 
260/280 ratio (dark grey) and the 260/230 ratio (light grey) as indicated by the NanoDrop 
spectrophotometer.  
	
 
Figure 5.5. Final RNA concentrations of samples for RNA sequencing. Histograms show final 
concentrations of RNA of all the RNA sequencing samples after DNase treatment.  
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5.4.2 Analysis of Ciz1 expression 
 
Since the investigation in this thesis revolves around Ciz1 it is important to first 
analyse the levels of gene expression of Ciz1 across the samples submitted for 
sequencing. This is important to control for possible anomalies and to ensure that the 
genetically modified cell lines have been successfully modified, given the design of 
the KO model (exon 1 highjack), and the propensity for alternative splicing in the Ciz1 
gene. Although the Ciz1 KO cell lines and the Ciz1 KO cell line with the inducible 
transgene (e13.17 Ciz1 KO), underwent checks when they were generated it is 
important to confirm it before starting to analyse the RNA sequencing results. As seen 
in Table 5.1, the three wild-type cell lines show very similar levels of expression which 
shows that Ciz1 expression is relatively consistent across these three individual wild-
type mice. In all three of the Ciz1 KO cell lines there is some Ciz1 expression but at 
significantly lower levels (p=	5.00E-05; q = 0.00515895), which are again similar 
across all three individuals. This shows that the Ciz1 gene, or most of it has been 
successfully suppressed with only a very small amount of leaky expression (Table 
5.1). This may also be ‘noise’ in the system and represent inaccurately mapped 
transcripts.  
 
Regarding the e13.17 Ciz1 KO inducible cell line, following induction with doxycycline, 
used at a concentration of 5μg/mL and for a period of 48 hours, Ciz1 is expressed 
(Table 5.1). However, levels of expression are overwhelmingly higher compared to 
the wild-type levels of expression, in agreement with prior qRT-PCR analysis.  
 
In the male cell lines, levels of Ciz1 expression are very similar to the female wild-
type (Table 5.1), suggesting there is no significant differences between the sexes. 
The same occurs for the female and male Ciz1 KO cell lines which again have very 
similar levels of low-level leaky Ciz1 expression.  
 
Finally, in the wild-type female spleen tissue sample the level of expression of Ciz1 
is almost double that observed in the female cell lines (Table 5.1). However, it is not 
possible to make a direct comparison between the two as they represent unrelated 
cell types. The spleen tissue sample from the Ciz1 KO female mouse however, has 
very similar low level expression compared to the female Ciz1 KO cell lines (Table 
5.1).  
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Table 5.1. Table showing levels of gene expression of Ciz1 across all RNA sequencing samples. 
For cases where more than one replicate was used, such as comparison of wild-type versus Ciz1 KO 
female cell lines, the number assigned to each replicate in the RNA sequencing is indicated (0-2). Levels 
of gene expression are indicated in Fragments Per Kilobase of transcript per Million mapped reads 
(FPKM values). p and q values (see Methods) for the WT vs Ciz1 KO female comparison are also 
indicated.  
	
5.4.3 Analysis of RNA sequencing data from X chromosome 
	
5.4.3.1 Analysis of gene expression from the X chromosome 
	
RNA sequencing data was initially processed by members of the bioinformatics group 
at the technology facility, which involved alignment of the reads to the genome of the 
C57BL/6 mouse, transcriptome assembly and analysis of differential gene expression 
(see Methods). Using the output of this analysis I created a summary table of results 
from the X chromosome (Table 5.2). This shows that gene expression between the 
wild-type and Ciz1 KO conditions remains predominantly unchanged, but that 2% of 
X-linked transcription units are de-regulated (Figure 5.6). From a total of 4273 
transcription units 85 have a p-value equal to or less than 0.05 (Table 5.2). A total of 
23 genes were manually excluded from this list, where no gene expression was seen 
in any of three replicates of one of the conditions, and two of the replicates of the 
other condition. Although a p and q value (see Methods) can still be calculated by the 
Cuffdiff software these genes were filtered out since, from a biological point of view, 
they are of no interest. Following this filtering, a total of 62 transcription units with p-
W
ild
-ty
pe
Replicate no. Sample FPKM Average p-value q-value
0 E14.4 WT ♀ 19.5346
21.9871
5.00E-05 0.00515895
1 E13.1 WT ♀ 23.2416
2 E13.8 WT ♀ 23.1852
C
iz
1
KO
0 E14.2 Ciz1 KO ♀ 0.270572
0.3222981 E13.15 Ciz1 KO ♀
0.362798
2 E13.17 Ciz1 KO ♀
0.333524
+ 
do
xy
cy
cl
in
e - E13.15 Ciz1 KO 
(+dox) ♀
0.250912 0.250912 - -
- E13.17 Ciz1 KO 
(+dox) ♀
330.331 330.331 - -
M
al
e 
sa
m
pl
es - E13.2 WT ♂ 22.1556 22.1556 - -
- E13.6 KO ♂ 0.242394 0.242394 - -
Sp
le
en
 
tis
su
e - Spleen WT ♀ 41.3976 41.3976 - -
- Spleen KO ♀ 0.250324 0.250324 - -
	
	
	
	
	
	
69	
value equal or less than 0.05 remained, of which 6 have positive q-values (Figure 
5.7).  
 
From these 62 transcription units, 34 are downregulated in the Ciz1 KO cell lines, 
while 28 are upregulated (Figure 5.7). This almost even distribution suggests that 
changes occurring across the X chromosome may not be directly linked to 
reactivation of the Xi, but are more likely to represent genome-wide changes 
occurring as a consequence of loss of Ciz1. If gene reactivation from the inactive X 
chromosome was occurring we would expect most genes to become upregulated in 
the Ciz1 KO condition, as a consequence of loss of repression. Even for those 
transcription units that are up-regulated no strong conclusions can be derived, as it is 
not possible, in this experiment, to specifically look at transcription from the inactive 
X chromosome in isolation from overall X chromosome expression. Furthermore, no 
specific regions within the X chromosome appear to be enriched within this list of 62 
affected transcription units (Figure 5.7).  
 
X chromosome 
x3 Wild-type vs x3 Ciz1 Knockout ♀ 
Total number of transcription units: 4273 
Status: OK (1720); NOTEST (2552); FAIL (1) 
Significant q-value: 9 , up-regulated (7)/down-regulated (2) 
P<0.05: 85; up-regulated (42)/down-regulated (43) 
P< 0.01: 41; up-regulated (22)/down-regulated (19) 
P<0.005: 29; up-regulated (17)/down-regulated (12) 
P<0.001: 14; up-regulated (9)/down-regulated (5) 
x1 Wild-type vs x1 Ciz1 KO spleen ♀ 
Total number of transcription units: 4273 
Status: OK (2209); NOTEST (2063); FAIL (1) 
Fold change > 0.3, < -0.3: 1986; up-regulated (960)/ down-regulated (1026) 
Fold change > 2, < -2: 827: up-regulated (420)/ down-regulated (407) 
x1 E13.17  Ciz1 KO (+dox) vs x1 E13.17 Ciz1 KO (-dox) ♀ 
Total number of transcription units: 4273 
Status: OK (1731); NOTEST (2542); FAIL (0) 
Fold change > 0.3, < -0.3: 1458 ; up-regulated (733)/ down-regulated (725) 
	
	
	
	
	
	
70	
Fold change > 2, < -2: 487: up-regulated (246)/ down-regulated (241) 
x1 E13.15 Ciz1 KO (+dox) vs x1 E13.15 Ciz1 KO (-dox) ♀ 
Total number of transcription units: 4273 
Status: OK (1843); NOTEST (2417); FAIL (13) 
Fold change > 0.3, < -0.3: 1725; up-regulated (840)/ down-regulated (885) 
Fold change > 2, < -2: 629: up-regulated (266)/ down-regulated (363) 
x1 E13.2 WT vs  x1 E13.6 Ciz1 KO ♂ 
Total number of transcription units: 4273 
Status: OK (1708); NOTEST (2555); FAIL(10) 
Fold change > 0.3, < -0.3: 1385; up-regulated (683)/ down-regulated (702) 
Fold change > 2, < -2: 410: up-regulated (186)/ down-regulated (224) 
Table 5.2. Table showing overview of RNA sequencing results for the X chromosome. For all 
comparisons where statistical results cannot be taken into account due to only having one replicate of 
each condition a threshold of +/- 0.3 fold change was applied to determine those genes with possible 
significant changes. This threshold was obtained by looking at the minimum fold change that rendered 
a significant p-value in the X chromosome and whole genome WT vs Ciz1 KO comparison, which have 
three replicates. In addition, the number of genes that are changed greater than 2 fold are indicated. For 
definitions of status terms (OK, NOTEST, FAIL) as well as transcriptional units see Methods.  
	
Figure 5.6. Histograms showing mean levels of gene expression in log scale, for all transcription 
units on the X chromosome, mapped against a schematic of the X chromosome, for wild-type cells 
(left) and Ciz1 KO cells (right). Small histograms on the right hand side represent examples of regions 
where changes can be seen between the wild-type and Ciz1 KO means. These areas are marked in red 
in the main figure.	Hyphens are used to indicate non-annotated genes. Genes where no expression is 
shown are examples of NO TEST outcomes. 	
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Figure 5.7. Heatmaps showing gene expression data for the 62 X-linked transcription units that 
are significantly changed (p<0.05) between wild-type and Ciz1 KO cell lines. Left, levels of gene 
expression (FPKM, with orange colour coded key), in log scale, plotted against an annotated schematic 
of the X chromosome (middle). Levels of gene expression represent the average of three replicates both 
for the WT and Ciz1 KO. Right, heat map shows fold-change in gene expression with red-green colour 
scale (red: downregulated; green: upregulated). Genes with a significant q-value are starred. Hyphens 
are used to indicate non-annotated transcription units. 
 
5.4.3.2 Genes from the X inactivation centre are not significantly affected 
as a consequence of Ciz1 KO 
	
The state of X chromosome repression was further analysed by looking at genes 
within the X inactivation centre (XIC), with known functions in the X inactivation 
process (Figure 5.8). No significant changes can be seen, except for Ftx, which does 
have a significant p-value (p = 0.02) but does not have a significant q value (q = 
0.603433). It is therefore reasonable to conclude that loss of CIZ1 does not have a 
direct effect on the well-established repressive mechanism originating at the XIC.  
 
Log2 (gene	
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Figure 5.8. Analysis of expression of genes within the X inactivation centre. Left, levels of gene 
expression (FPKM, with orange colour coded key), in log scale, plotted against an annotated schematic 
of the X chromosome (middle), where the X inactivation centre is indicated with a red square. Levels of 
gene expression represent the average of three replicates both for the WT and Ciz1 KO. Right, heat 
map shows fold-change in gene expression with red-green colour scale (red: downregulated; green: 
upregulated). 
 
5.4.3.3 Female and male mouse cell lines show different response to Ciz1 
KO 
 
The 62 transcription units that are significantly changed (p<0.05) in the female cell 
line following Ciz1 KO were further analysed by looking at their levels of expression 
in the male WT and male Ciz1 KO cell line (Figure 5.9). A total of 33 transcription 
units are differentially affected by loss of Ciz1 in female compared to male cells. 
These were selected based on opposite patterns of gene expression in the female 
compared to the wild-type, for example a transcription unit that is significantly 
upregulated in the female Ciz1 KO but downregulated in the male Ciz1 KO, or vice 
versa. A further 9 genes were added to the list of differentially expressed genes since 
although the fold change occurred in the same direction, the difference is at least 
three times higher in one of the sample sets.  That makes a total of 42 genes out of 
62 that respond differently to knockout of Ciz1 in female and male samples. The six 
genes that have a significant q-value in the female list, and could therefore be of most 
interest were picked as examples to illustrate this outcome (Figure 5.9). Four out of 
the six q-positive genes showed differences between female and male cells; Agtr2, 
Log2 (gene	
expression,	 FPKM)
Log2 (fold	 change)
X3 WT x 3 Ciz1 KO Log2 (Ciz1 KO/WT)
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Gpm6b, Tmem164 and a non-annotated gene with locus X:	079926530-079993730. 
These results suggest that although the female specific lymphoma might not be 
related to X chromosome inactivation other secondary changes that occur as a 
consequence of the loss of CIZ1, and that affect the female and male cells differently 
could underlie the phenotype.  
 
	
Figure 5.9. Heatmap represents fold-change of gene expression of the 62 genes with significant 
p-values (p<0.05) in the Ciz1 KO compared to the wild-type cell lines in female and male samples. 
Left, heatmap represents fold-change in female samples obtained from the average of three replicates 
for both WT and Ciz1 KO cell lines. Right, data for the same genes derived from one single male replicate 
each for the WT and Ciz1 KO.  A red-green colour scale represents levels of fold change (red: 
downregulated; green: upregulated). Non annotated genes are indicated with a hyphen.  
5.4.3.4 Re-expression of Ciz1 in a Ciz1 KO cell line restores wild-type 
levels of gene expression for some genes 
 
To test whether re-expression of Ciz1 in a Ciz1 KO background is capable of restoring 
wild-type levels of expression the previously described e13.17 Ciz1 KO cell line was 
used. Upon addition of doxycycline to culture media GFP-CIZ1 is expressed and 
targeted to the Xi, as shown previously for transcript and fluorescent protein (Figure 
5.2 and Figure 5.3). The six genes with significant q-values were picked as examples 
to investigate this question, and further compared to the effect of doxycycline on a 
Log2(Ciz1 KO/WT)
Female ♀ (x3) Male ♂ (x1)
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Ciz1 KO cell line that does not contain the transgene (e13.15), to introduce a control 
for possible direct effects of doxycycline. Any gene with a change in gene expression 
in the same direction, and greater than 0.5% of that in the transgenic e13.17 Ciz1 KO 
cell line was ruled out of further analysis. This affected 44% of the 62 genes but none 
of the six genes with significant q-values, (data not shown). Since it is also of interest 
to look for genes that are differentially affected by knockout of Ciz1 between female 
and male in order to try and find links with the lymphoma-like phenotype these same 
six genes were also picked as candidates to look for differences between female and 
male cells (Figure 5.10).  
	
Figure 5.10. Histograms showing analysis of female versus male and Ciz1 re-induction analysis 
for the six q-significant transcription units from the X chromosome. For each gene the first bar 
represents mean female wild-type levels of expression. The next two bars represent levels of expression 
in Ciz1 KO female cell lines (mean) and induced e13.17 Ciz1 KO cell line, respectively. On the right-
hand side of each histogram the first bar shows male wild-type levels of expression. The next bar 
represents levels of expression in Ciz1 KO male cell line. The female WT and Ciz1 KO bars represent 
the average of three replicates while all other bars represent data from one single replicate. Error bars 
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on the first to bars of each histogram represent standard error of the mean calculated from three 
replicates.   
 
5.4.3.5 Comparative analysis of X-linked genes affected by loss of 
CIZ1 with existing literature on X inactivation 
	
In the mouse approximately 3.3% of genes escape XCI and remain transcriptionally 
active, (Yang et al, 2010), many of which are thought to have female-specific 
functions that contribute to sexual dimorphism (Berletch et al, 2011). The subset that 
escape silencing vary between cell type and developmental stage (Gendrel et al, 
2012), with some genes (constitutive escapees) avoiding silencing in most cell types, 
and others (facultative escapees) only in specific contexts. Although no significant 
overlap of our list with constitutive escapees has been observed other comparisons 
of interest have been made. 
 
Direct comparison of a subset of our X-linked genes significantly affected by loss of 
Ciz1 (Table 5.3) with the list of genes obtained from studies of escape from X 
inactivation revealed that in fact, a total of five genes, have been described as 
facultative escapees, only escaping X inactivation in specific mouse tissues (Berletch 
et al, 2015). It has been suggested that genes that escape X inactivation are likely 
those involved in female specific functions (Berletch et al, 2011). In addition, escape 
of X inactivation might specifically occur in those tissues where the gene exerts its 
functions. An example is the Gpm6b gene, which escapes X inactivation in brain 
tissue, and has been reported to have nervous system related functions, namely in 
the myelination of the central nervous system (Werner et al, 2013). Interestingly, 
expression changes in this gene have also been detected in the cerebellum of 
Alzheimer’s mouse models (Bao, 2008), suggesting a possible link with the disease. 
Interestingly CIZ1 itself has also been implicated in the disease (Dahmcke et al, 
2008). Moreover, Alzheimer’s is more likely to develop in females than in males (Viña 
and Lloret, 2010), revealing a sex-bias. This was originally attributed to hormonal 
differences, however trials involving hormone replacement therapy have not shown 
any evidence for it (Brinton, 2004). It is therefore possible that other female-specific 
differences such escape of X inactivation might be accountable for this risk factor 
difference between the sexes. Another example gene is Cfp which encodes the 
properdin protein and is involved in positive regulation of complement activation in 
the immune system (Lesher et al, 2013).  This gene, which is significantly affected by 
loss of CIZ1, escapes X inactivation in the spleen, which is also the tissue from which 
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the properdin protein is produced (Maves and Weiler, 1992). Interestingly, Cfp has 
been implicated in several autoimmune disorders (Holers, 2008), which are known to 
affect women more than men (Fairweather et al, 2008). Importantly, this gene, which 
is significantly upregulated following Ciz1 KO, also overlaps with the list of genes that 
are known to be significantly upregulated upon knockdown of Xist in the blood 
compartment of mice (Yildirim et al, 2013), revealing a possible common mechanism 
that upon disruption leads to upregulation of the gene. 
 
Two transmembrane protein coding genes, Tmem164 and Tmem29, also overlap 
with the list of genes of the same study, being defined as genes that escape X 
inactivation in the ovary (Berletch et al, 2015). This is again interesting, since both 
genes are expressed in an organ with female specific functions. In addition, 
Tmem164 gene, which is overexpressed following knockout of Ciz1, is also 
overexpressed following knockdown of Xist (Yildirim et al, 2013) and Smchd1 
(Gendrel et al, 2013).  
 
 
Table 5.3. Table comparing a subset of X-linked genes significantly affected by Ciz1 KO with 
results from other X-inactivation studies. First half of the table aims to assess whether the X-linked 
Genes  
 
 
 
 
Escapees of X inactivation Other knockdown studies 
 
(Berletch et al, 
2015) 
Others Studies with 
no overlap 
Xist 
knockdown 
(Yildrim et 
al, 2013) 
Firre 
knockdown 
(Yang et al, 
2015) 
Smchd1 
(Gendrel et al, 
2013) 
Was   (Yang et al, 
2010);PMID: 
20363980 
   
Timp1   (Anderson 
and Brown, 
2002);PMID: 
11935340 
   
Cfp Tissue specific 
(spleen) 
 (Calabrese 
et al, 
2012);PMID: 
23178118 
   
Agtr2   (Li et al, 
2012); PMID: 
22384067 
   
Wdr44       
Dcaf12       
Stk26       
Fhl1  (Finn et al, 
2014);PMID: 
24594094 
    
Fgf13       
Dusp9       
Rpl3-ps2       
Efnb1       
Ftx Tissue specific 
(brain, spleen, 
ovary) 
(Pinter el al, 
2012);PMID: 
22948768 
    
Zcchc5       
Nup62cl       
Tmem164 Tissue specific 
(ovary) 
     
Capn6       
Amot       
Tmem29 Tissue specific 
(ovary) 
     
Klf8       
Rps6ka3       
Figf       
Gpm6b Tissue specific 
(brain) 
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gene list is enriched for genes known to escape X inactivation. A list of studies that do not show overlap 
with my list are also listed (these studies do not correlate to the genes on the first column). Second half 
of the table compares the list of X-linked genes known to be affected by loss of Ciz1 with the list of genes 
that are known to be affected by knockdown of other players of X inactivation such as Xist, Firre, and 
Smchd1 genes. Grey shaded areas indicate overlapping genes in the two lists.  
	
	
5.4.4 Analysis of RNA sequencing data from the whole genome 
	
5.4.4.1 Overview of gene expression from the whole genome 
 
For the whole genome RNA sequencing data, I also generated a summary table of 
results (Table 5.3). Initial analysis shows that 2.6% of transcription units are 
significantly changed between the wild-type and Ciz1 KO conditions. From a total of 
56417 transcriptional units 1480 genes have a p-value equal or less than 0.05 (Table 
5.3). This will be referred to as CIZ1-1480. It is important to note that the overall rate 
of significance is similar between the whole genome, 2.6% and the X chromosome, 
2%, suggesting that the previous effect observed at the X chromosome is likely 
caused via the same mechanisms observed in the whole genome.  
 
Whole genome 
x3 Wild-type vs x3 Knockout ♀ 
Total number of transcription units: 56417 
Status: OK (16715); NOTEST (39700); FAIL (2) 
Significant q-value: 286, up-regulated (136)/down-regulated (150) 
P<0.05: 1480; up-regulated (821)/down-regulated (659) 
P< 0.01: 914; up-regulated (564)/down-regulated (350) 
P<0.005: 788; up-regulated (500)/down-regulated (288) 
P<0.001: 298; up-regulated (142)/down-regulated (156) 
x1 Wild-type vs x1 KO spleen ♀ 
Total number of transcription units: 56417 
Status: OK (24869); NOTEST (31539); FAIL (2); LOWDATA (7) 
Fold change > 0.3, < -0.3: 24585; up-regulated (13629)/ down-regulated (10956) 
x1 E13.17 KO (+dox) vs x1 E13.17 KO (-dox) ♀ 
Total number of transcription units: 56417 
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Status: OK (17360); NOTEST (39057); FAIL (0) 
Fold change > 0.3, < -0.3: 15722; up-regulated (8621)/ down-regulated (7101) 
x1 E13.15 KO (+dox) vs x1 E13.15 KO (-dox) ♀ 
Total number of transcription units: 56417 
Status: OK (18244); NOTEST (38164); FAIL (9) 
Fold change > 0.3, < -0.3: 18201; up-regulated (8946)/ down-regulated (9255) 
x1 E13.2 WT vs  x1 E13.6 KO ♂ 
Total number of transcription units: 56417 
Status: OK (17190); NOTEST (39221); FAIL (6) 
Fold change > 0.3, < -0.3: 15220; up-regulated (7712)/ down-regulated (7508) 
 
Table 5.4. Overview of RNA sequencing results for the whole-genome. For all comparisons where 
statistical results cannot be taken into account due to only having one replicate of each condition a 
threshold of +/- 0.3 fold change was applied to determine those genes with possible significant changes. 
This threshold was obtained by looking at the minimum fold change that rendered a significant p-value 
in the X chromosome and whole genome WT vs KO comparison, which have three replicates. For 
definitions of status terms (OK, NOTEST, FAIL) as well transcriptional units see Methods, Table 2.7.  
 
5.4.4.2 The list of genes that are significantly affected by knockout of Ciz1 
in the whole genome is enriched for PRC1 and PRC2 target genes 
	
Initial analysis of the gene expression data from the whole genome used the Gene 
Set Enrichment Analysis (GSEA) software. The aim is to look for enriched gene sets 
within the list of genes with significant changes in the wild-type versus Ciz1 KO 
comparison, where p<0.05. The GSEA software also applies statistical tests which 
return both p and q values that reflect the degree of overlap between CIZ1-1480 and 
specific gene sets. Of the 1480 CIZ1-related transcription units, 821 are up-regulated 
and 659 are down-regulated (Table 5.3).  
 
CIZ1-1480 was run first through the GSEA computational software, selecting the 
‘curated’ gene set. As defined by the Broad Institute this represents ‘gene sets 
collected from various sources such as online pathway databases, publications in 
PubMed, and knowledge of domain experts’ (Subramanian et al, 2005) (Mootha et al, 
2003). This initial analysis returned  some striking results, which show that CIZ1-1480 
is enriched for genes that are targets of both PRC1 and PRC2 subunits (Table 5.4). 
The extremely high statistical significance provided by both the p and q values 
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emphasizes this finding. This link to PRC1 and PRC2 subunits was also obtained 
when running GSEA ‘oncogenic signature’ gene set. As defined by the Broad Institute 
this gene set represents ‘signatures of cellular pathways which are often dis-regulated 
in cancer’. This analysis shows CIZ1-1480 is enriched for genes that are known to be 
either up-regulated or downregulated upon knockdown of genes that encode subunits 
of the PRC1 (BMI1 and MEL18), and PRC2 (EZH2) complexes (Table 5.5). 
 
 
Table 5.5. Table showing overlap with curated gene sets returned by GSEA. These gene sets 
include targets of known PRC1 subunits, such as BMI1, as well as targets of known PRC2 subunits, 
such as SUZ12, EED and EZH2. For a detailed description of GSEA terms see Methods, Table 2.8.  
 
 
 Table 5.6. Table showing overlap with oncogenic signatures returned by GSEA. These gene sets 
include genes that are known to be either upregulated or downregulated following knockdown of PRC1 
subunits, such as BMI1 and MEL18, as well as PRC2 subunits, such as EZH2. For a detailed description 
of GSEA terms see Methods, Table 2.8.  
CURATED GENE SETS
Gene set name Description Genes in overlap/ genes in gene set p/q value
BMI1_TARGETS_UP
(Douglas et al, 2008)
Genes up-regulated in A4573 cells 
(Ewing's sarcoma, ESFT) after knockdown 
of BMI1 [GeneID=648] by RNAi.
64/566 p =1.26E-29
q = 7.84E-28
SUZ12_TARGETS
(Ben-Porath et al, 2008)
Set 'Suz12 targets': genes identified by 
ChIP on chip as targets of the Polycomb
protein SUZ12 [GeneID=23512] in human 
embryonic stem cells.
120/1038 p = 2.70E-56
q = 1.06E-53
EED_TARGETS
(Ben-Porath et al, 2008)
Set 'Eed targets': genes identified by ChIP
on chip as targets of the Polycomb protein 
EED [GeneID=8726] in human embryonic 
stem cells.
113/1062 p = 2.72E-49
q = 7.57E-47
EZH2_TARGETS_UP
(Nuytten et al, 2008)
Genes up-regulated in PC3 cells (prostate 
cancer) after knockdown of EZH2 
[GeneID=2146] by RNAi.
125/1037 p = 9.11E-61
q = 4.78E-58
ES_WITH_H3K27ME3
(Ben-Porath et al, 2008)
Set 'H3K27 bound': genes posessing the 
trimethylated H3K27 (H3K27me3) mark in 
their promoters in human embryonic stem 
cells, as identified by ChIP on chip.
111/1118 p = 1.86E-45
q = 4.00E-43
ONCOGENIC SIGNATURES
Gene set name Description Genes in overlap/ genes in gene set Statistical test
BMI1_DN.V1_UP
(Wiederschain et al, 2007)
Genes up-regulated in DAOY cells 
(medulloblastoma) upon knockdown of 
BMI1 [Gene ID=648] gene by RNAi.
37/147 p = 2.67E-30
q = 5.05E-28
BMI1_DN.V1_DN
(Wiederschain et al, 2007)
Genes down-regulated in DAOY cells 
(medulloblastoma) upon knockdown of 
BMI1 [Gene ID=648] gene by RNAi.
13/144 p = 5.44E-06
q = 1.08E-05
MEL18_DN.V1_UP
(Wiederschain et al, 2007)
Genes up-regulated in DAOY cells 
(medulloblastoma) upon knockdown of 
PCGF2 [Gene ID=7703] gene by RNAi.
36/141 p = 9.34E-30
q = 8.82E-28
MEL18_DN.V1_DN
(Wiederschain et al, 2007)
Genes down-regulated in DAOY cells 
(medulloblastoma) upon knockdown of 
PCGF2 [Gene ID=7703] gene by RNAi.
30/148 p = 7.23E-22
q = 1.14E-20
PRC2_EZH2_UP.V1_UP
(Bracken et al, 2006)
Genes up-regulated in TIG3 cells 
(fibroblasts) upon knockdown of EZH2 
[Gene ID=2146] gene.
16/195 p = 1.66E-06
q = 3.48E-06
PRC2_EZH2_UP.V1_DN
(Bracken et al, 2006)
Genes down-regulated in TIG3 cells 
(fibroblasts) upon knockdown of EZH2 
[Gene ID=2146] gene.
23/194 p = 6.34E-12
q =2.49E-11
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The GSEA analysis also returned highly significant overlaps with gene sets implicated 
in other pathways and diseases such as cancer, however given the vast amount of 
data derived from this RNAseq data set it is not possible for me to analyze all of it in 
the course of one year. In addition, the relevance of some of these results in the 
context of CIZ1 biology is not clear and will require intense research. Furthermore, 
the hits implicating PRC complexes are of more relevance in this thesis due to their 
role in the process of X inactivation. In the following analysis, I have chosen to focus 
on one subunit from the PRC1 complex, BMI1, and one subunit from the PRC2 
complex, EZH2, looking at data from both the curated gene set analysis and 
oncogenic signature analysis. 
 
The curated gene set analysis shows that CIZ1-1480 is enriched for genes that are 
known to be upregulated in a female cancer cell line (A4573, Ewing sarcoma) 
following knockdown of BMI1 (Table 5.4). It also shows it to be enriched for genes 
that are known to be upregulated in prostate cancer cells following knockdown of 
EZH2 (Table 5.4). These were plotted in a heat map showing expression in the wild-
type versus Ciz1 KO female cells (Figure 5.11). A total of 12 genes appear in both 
lists, suggesting there is some degree of overlap between these pathways. 
Interestingly, even though the genes are known to be upregulated upon knockdown 
of BMI1 and EZH2, respectively, the majority are downregulated upon knockdown of 
Ciz1 for both gene sets, suggesting the expression profile that we are observing might 
be more characteristic of an overexpression of these two subunits rather than a 
knockdown effect.   
 
The oncogenic signature analysis shows that CIZ1-1480 is enriched for genes that 
are upregulated in DAOY cells (medulloblastoma) upon knockdown of BMI1. From a 
total of 147 genes that appear in this gene set, 37 overlap with CIZ1-1480 (p=	2.67E-
30, q =	5.05E-28) (Table 5.5). In addition, CIZ1-1480 is also enriched for genes that 
are downregulated in DAOY cells upon knockdown of BMI1, with a total of 13 genes 
overlapping out of 144 (p=5.44E-06, q=1.08E-05) (Table 5.5). When looking at levels 
of expression of the overlapping genes in the wild-type versus Ciz1 KO, results show 
that those genes in the downregulated category are upregulated in CIZ1-1480 and 
vice versa (Figure 5.12A-B). This begins to suggest that the expression profile 
observed in Ciz1 KO cells is more characteristic of an overexpression of BMI1 rather 
than a knockdown or downregulation, and is an unexpected finding.  
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The oncogenic signature analysis also shows that CIZ1-1480 is enriched for genes 
that are upregulated in TIG3 cells (fibroblasts) upon knockdown of EZH2. From a total 
of 195 genes in this gene set, 16 overlap with CIZ1-1480 (p=	1.66E-06, q =	3.48E-
06) (Table 5.5).  CIZ1-1480 is also enriched for genes that are downregulated in TIG3 
cells upon knockdown of EZH2 with a total of 23 genes overlapping out of 194 total 
genes in the gene set (p=	6.34E-12, q =	2.49E-11) (Table 5.5). When looking at their 
levels of expression, in both categories the majority of genes are downregulated 
following Ciz1 KO. (Figure 5.12A-B).  
 
 
Figure 5.11. Heatmaps showing wild-type versus Ciz1 KO fold change of gene expression of 
genes upregulated upon knockdown of A) BMI1 or B) EZH2, that overlap with CIZ1-1480. Data has 
been obtained from the average of three replicates for both WT and Ciz1 KO cell lines. A red-green 
colour scale represents levels of fold change (red: downregulated; green: upregulated).  
 
BMI1_TARGETS_UP EZH2_TARGETS_UP
Log2(Ciz1 KO/WT) Log2(Ciz1 KO/WT)
A) B)
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Figure 5.12. Heatmaps showing wild-type versus Ciz1 KO fold change of gene expression of 
genes that overlap between CIZ1-1480 and some of the gene sets returned by the oncogenic 
signatures analysis. From left to right: genes known to be upregulated upon knockdown of BMI1, genes 
known to be downregulated upon knockdown of BMI1, genes known to be upregulated upon knockdown 
of EZH2 and genes known to be downregulated upon knockdown of EZH2. Data has been obtained 
from the average of three replicates for both WT and Ciz1 KO cell lines. A red-green colour scale 
represents levels of fold change (red: downregulated; green: upregulated.  
 
With so many target genes of PRC1 and PRC2 subunits affected by loss of CIZ1, we 
might expect to see significant changes in gene expression of the subunits 
themselves. Remarkably, gene expression levels of the PRC1 and PRC2 subunits is 
not affected as a consequence of Ciz1 KO (Table 5.6).  
BMI1_DN.V1_UP BMI1_DN.V1_DN PRC2_EZH2_UP.V1_DNPRC2_EZH2_UP.V1_UP
Log2(Ciz1 KO/WT)
	
	
	
	
	
	
83	
	
	
Table 5.7. Expression of genes encoding PRC1 and PRC2 subunits are not affected by knockout 
of Ciz1. Table shows mean gene expression in FPKM of genes encoding PRC1 subunits (BMI1, MEL18) 
and PRC2 subunits (EZH2, SUZ12, EED), in the wild-type female cells versus Ciz1 KO female cells. p 
and q values indicate that levels of expression are not significantly different between the two conditions.  
	
5.4.4.3 Genes affected by knockdown of BMI1 are differentially affected in 
female and male cell lines 
	
Since analysis of gene expression from the X chromosome has not shown strong 
evidence that it could underlie the female gender-bias of the lymphoma-like 
phenotype observed in Ciz1 KO mice, I investigated whether some of the autosomal 
gene targets of PRC1 and PRC2 are differentially affected by Ciz1 KO in female 
versus male cell lines. Since BMI1 has established links with lymphoma (Raaphorst, 
2005) I will look specifically at the genes within the BMI1 gene sets, more specifically 
those that are upregulated by knockdown of BMI1 (BMI1_DN.V1_UP) in the 
oncogenic signature analysis, which includes a total of 37 genes (Table 5.5). Analysis 
of the fold change in gene expression between Ciz1 KO and WT cells for these 37 
genes (Figure 5.13), reveals 18 that are differentially affected between female and 
male cells. This includes 15 genes with opposite patterns of expression, that is where 
a gene is upregulated in the female as a consequence of Ciz1 KO but downregulated 
in the male, or vice versa. It also includes three genes where the change occurs in 
the same direction but the fold change is at least three times greater in one of them. 
It is important to take into account that this analysis only includes one replicate for 
each of the male samples and therefore no statistical analysis can be carried out. 
However, all three replicates for the female samples are internally consistent which 
PRC1/PRC2 genes
Gene WT Ciz1 KO p-value q-value
BMI1 15.9396 14.2735 0.6403 0.999858
MEL18 14.9691 18.4002 0.24695 0.999858
EZH2 12.1375 12.0017 0.94195 0.999858
SUZ12 12.0546 11.9928 0.964 0.999858
EED 36.1997 34.9442 0.86835 0.999858
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suggests the same might occur for the males. If any further work was to be derived 
from this analysis female versus male comparisons would need repeating with 
enough replicates to obtain statistical significance or validation of candidate genes by 
qPCR. 
 
 
Figure 5.13. Analysis of female versus male differences following Ciz1 knockout for genes known 
to be affected by knockdown of BMI1. Left, heatmap shows fold change between wild-type and Ciz1 
KO female cells.  Right, heatmap shows fold change for the same genes between wild-type and Ciz1 
KO male cells. The genes shown are the 37 that overlap between the oncogenic signature gene set that 
are upregulated upon knockdown of BMI1 and CIZ1-1480. Data has been obtained from the average of 
three replicates for both WT and Ciz1 KO female cell lines and from one single replicate for the male 
data. A red-green colour scale, indicated by the colour key, represents levels of fold change (red: 
downregulated; green: upregulated). 
 
5.4.4.4. Re-expression of Ciz1 in a Ciz1 KO background reinstates wild-type 
levels of gene expression for some genes 
 
A Ciz1 KO inducible cell line (13.17) exposed to 5µg/mL of doxycycline for a period 
of 48 hours was included in the RNA sequencing in order to test whether re-
expression of Ciz1 is capable of restoring wild-type levels of expression. Once again, 
Fold change Ciz1 
KO/WT (female)
Fold change Ciz1 
KO/WT (male)
Log2(Ciz1 KO/WT)
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I will focus my analysis on the same small subset of genes, the 37 genes that overlap 
with the BMI1_DN.V1_UP gene set. As shown in Figure 5.14 reinstatement to wild-
type levels occurs following re-expression of Ciz1 for at least six example genes. In 
other cases, slight reinstatement occurs but fails to reach wild-type levels. It is 
possible that in these cases a longer exposure could completely reinstate wild-type 
levels.  In addition, for some genes no reinstatement is observed or in fact addition of 
doxycycline causes levels of expression to drift even further from wild-type status 
(Figure 5.15). A total of 14 genes were discarded from the analysis since the control 
cell line, e13.15 KO exposed to dox, showed gene expression to be affected by the 
presence of doxycycline. From the remaining candidate genes 15 showed no 
reinstatement while 8 did show reinstatement of wild-type levels.  
 
 
Figure 5.14. Histograms showing six example genes where re-expression of Ciz1 in a Ciz1 KO 
background reinstates wild-type levels of gene expression. The first bar in each histogram 
represents wild-type levels of expression, which have been normalised to 1. Levels of expression in the 
Ciz1 KO cell line and the induced e13.17 Ciz1 KO cell line, showed in the second and third bar, 
respectively, are expressed relative to wild-type levels.  The WT and Ciz1 KO bars represent the average 
of three replicates while the Ciz1 KO (+dox) cell line represents data from one single replicate.  
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Figure 5.15. Example genes where re-expression of Ciz1 in a Ciz1 KO background fails to 
reinstate wild-type levels of expression. The first bar in each histogram represents wild-type levels of 
expression, which have been normalised to 1. Levels of expression in the Ciz1 KO cell line and the 
induced e13.17 Ciz1 KO cell line, showed in the second and third bar, respectively, are expressed 
relative to wild-type levels.  The first histogram shows levels of expression of the Lhfpl2 gene, an example 
where re-expression of Ciz1 does not cause any changes in gene expression compared to the Ciz1 KO 
cell line. The second histogram shows levels of expression of the Has2 gene and constitutes an example 
where re-expression of Ciz1 cause levels of expression to drift even further from wild-type levels. The 
WT and Ciz1 KO bars represent the average of three replicates while the Ciz1 KO (+dox) cell line 
represents data from one single replicate.  
 
5.4.4.5 Genes affected by knockdown of BMI1 are good candidates for the 
female specific lymphoma 
	
It is possible that the female-specific lymphoma-like phenotype could be linked to 
some of the genes that are known to be affected by knockdown of BMI1. Good 
candidate genes would likely be differentially affected in female and male cells lines, 
although these results must be interpreted with caution due to the absence of 
replicates. Genes which are capable of reaching wild-type levels of expression upon 
re-expression of Ciz1 could also be of interest since they are most likely those that 
are more directly affected by loss of the protein and therefore more dependent of it. 
Three genes from the list of 37 genes meet all of these criteria: Cxcl1, Vegfc, and 
Anxa3 (Figure 5.16). All three genes have significant p-values in the wild-type versus 
Ciz1 KO comparison and significant p and q values reported by the GSEA software 
make them of great interest. Cxcl1 and Vegfc are upregulated upon loss of Ciz1, with 
a fold change of 1.29 and 0.58 respectively. Anxa3 on the other hand is 
downregulated, with a fold change of -0.33.  
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A) 
 
 
B) 
 
  C) 
 
Figure 5.16. Histograms showing analysis of female versus male and Ciz1 re-induction analysis 
for three genes that are candidate mediators of the lymphoma-like phenotype. For each gene the 
first bar represents female wild-type levels of expression, which have been normalised to 1. The next 
two bars represent levels of expression in Ciz1 KO female cell lines and induced e13.17 Ciz1 KO cell 
line, respectively, which have been expressed relative to the normalised wild-type level. On the right-
hand side of the histograms the first bar shows male wild-type levels of expression, which have also 
been normalised to 1. The next bar represents levels of expression in Ciz1 KO male cell line, expressed 
relative to the normalised male wild-type level. The female WT and female Ciz1 KO bars represent the 
average of three replicates while all other bars represent data from one single replicate. 
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5.4.4.6 Immune function related genes are also affected by knockout of 
Ciz1 
	
Since 100% of Ciz1 KO female mice that were analysed in detail were found to have 
developed a lymphoma-like phenotype, we might expect to see changes in genes 
with functions linked to the immune system. In fact, when analysing the list of 1,480 
genes that are differentially expressed between WT and Ciz1 KO female cell lines 
using the GSEA Gene Ontology (GO) biological process gene set, a total of 25 genes 
were found to overlap with the immune system process gene set, which has a total 
of 332 genes (GO:0002376). This 7.5% representation returned a p	value	of	1.23E-
08, and a q	value	of	1.39E-07, indicating biological significance. Since the lymphoma-
like phenotype is specific to female mice we would also expect to see that some of 
these genes are differentially affected between female and male cells (Figure 5.17). 
In fact, a total of seven of these 25 immune-linked genes have opposite patterns of 
expression between female and male Ciz1 KO cells, and one further gene (Rsad2), 
is of interest since, although upregulated in both, it is more than three times higher in 
the female.  
	
Figure 5.17. Analysis of female versus male differences in gene expression following Ciz1 
knockout for immune-linked genes. The genes shown on the heatmap are genes that overlap 
between CIZ1-1480 and the list of genes that are included in the immune system functions gene set as 
Log2(Ciz1 KO/WT)
Fold change Ciz1 
KO/WT (female)
Fold change Ciz1 
KO/WT (male)
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defined by biological process gene set in the GSEA software.  Data has been obtained from the average 
of three replicates for both WT and Ciz1 KO female cell lines and from one single replicate for the male 
data. A red-green colour scale, indicated by the colour key, represents levels of fold change (red: 
downregulated; green: upregulated).  
 
5.4.4.7 Summary section of other interesting results of gene ontology 
analysis 
 
In addition to the results described above, the gene set enrichment analysis also 
returned other interesting results, which will possibly become subject of further 
research in the future. However, with the intention of keeping a written record I have 
gathered some of these results and compiled a table. Some of the hits of the GSEA 
software have not been included since they are not relevant to my investigation, e.g: 
genes consistently up-regulated in mammary stem cells both in mouse and human 
species.  
 
The first result in Table 5.8. indicates that CIZ1-1480 is enriched for genes that are 
known to be upregulated in the brain of patients with Alzheimer’s disease (p= 1.93E-
40, q = 3.14E-38). This constitutes a striking result since a splice variant of Ciz1 has 
been reported to be upregulated in the brain of Alzheimer’s patients (Dahmcke et al, 
2008).  
 
CIZ1-1480 is also enriched for genes that are known to be upregulated in breast 
cancer cells after knockdown of SATB1. This is of interest because SATB1 is a 
scaffold or matrix-associated region (S/MAR) binding protein which has been linked 
with chromatin organization and is thought to have a role in Xist-mediated silencing 
although its exact role is still unclear (Tattermusch and Brockdorff, 2011).  
 
All other results in Table 5.8 show that CIZ1-1480 is also enriched for genes that are 
known to be either upregulated or downregulated in several types of cancer including 
urothelial carcinoma, breast cancer, prostate cancer, papillary thyroid carcinoma and 
pediatric adrenocortical tumours. These are just some of the examples of gene set 
enrichment results that link loss of CIZ1 to cancer. These observations are of great 
interest because CIZ1 has already been linked with cancers such as breast cancer 
(den Hollander et al, 2006), lung cancer (Higgins et al, 2012), hepatocellular 
carcinoma (Wu et al, 2015) and Ewing sarcoma (Rahman et al, 2007). These results 
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could shed some light on the CIZ1-related pathways that are being affected during 
the development of cancer.  
 
	
Table 5.8. Examples of other results of interest obtained from the gene set enrichment analysis 
on genes that are significantly affected (p<0.05) by knockout of Ciz1.  
 
5.5 Discussion 
	
One of the aims of this work was to investigate, whether the changes that have been 
observed at the inactive X in the absence of CIZ1, such as delocalization of Xist and 
disruption of the H3K27 methylation mark, impact on X-linked gene expression. More 
specifically, whether there is evidence for gene reactivation from the inactive X. 
Results show that gene expression remains largely unchanged, which is in line with 
similar analyses of X-linked transcript reactivation following disruption of known 
players of X inactivation in somatic cells. Examples are derived from disruption of 
genes within the X inactivation centre (Brown and Willard, 1994) or nuclear matrix 
proteins with important functions in X inactivation such as Saf-A (Hasegawa et al, 
2010) and Firre (Yang et al, 2015), knockout of which leads to disruption of the 
H3K27me3 but not reactivation of the inactive X. The small number of significant 
changes (%2 of transcription units) in gene expression that were observed following 
Ciz1 knockout seem to be evenly distributed over the X chromosome and, given the 
design of this experiment, it is not possible to specifically identify X-linked expression 
from Xi, therefore strong conclusions about the 28 upregulated genes in relation to Xi 
CURATED GENE SETS
Gene set name Description Genes in overlap/ genes in gene 
set
Statistical test
BLALOCK_ALZHEIMERS_DISEASE
_UP
Genes up-regulated in brain from 
patients with Alzheimer's disease.
129/1691 p = 1.93E-40
q = 3.14E-38
HAN_SATB1_TARGETS_UP Genes up-regulated in MDA-MB-231 
cells (breast cancer) after knockdown of 
SATB1 [GeneID=6304] by RNAi.
53/395 p = 2.47E-28
q = 1.44E-26
LINDGREN_BLADDER_CANCER_C
LUSTER_2B
Genes specifically up-regulated in 
Cluster IIb of urothelial cell carcinoma 
(UCC) tumors.
74/392 p = 7.09E-50
q = 2.09E-47
SMID_BREAST_CANCER_LUMINA
L_B_DN
Genes down-regulated in the luminal B 
subtype of breast cancer.
83/564 p = 4.91E-47
q = 1.22E-44
LIU_PROSTATE_CANCER_DN Genes down-regulated in prostate 
cancer samples.
76/481 p = 2.23E-45
q = 4.58E-43
DELYS_THYROID_CANCER_UP Genes up-regulated in papillary thyroid 
carcinoma (PTC) compared to normal 
tissue.
71/443 p = 7.28E-43
q = 1.32E-40
WEST_ADRENOCORTICAL_TUMO
R_DN
Down-regulated genes in pediatric 
adrenocortical tumors (ACT) compared 
to the normal tissue.
75/546 p = 2.04E-40
q = 3.21E-38
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reactivation cannot be made. Furthermore, none of the genes at the XIC with 
important functions in the initiation of X chromosome inactivation, such as Xist (Plath 
et al, 2002), Tsix (Lee et al,1999), Jpx (Tian et al, 2010), Ftx (Chureau et al, 2011) 
are affected by knockout of Ciz1. This indicates that, if indeed CIZ1 has a role in X 
chromosome inactivation, it is likely not in the initiation stage of XCI.  
Overall it is clear that widespread gene reactivation does not occur when CIZ1 is 
removed, nevertheless Ciz1 could still have a function in the maintenance of X 
inactivation, as the multiple layers of control are unlikely to be breached by loss of 
one factor. The results are consistent with the previous observation that Ciz1 KO 
embryos develop normally (Ainscough, unpublished), and contrasts with the lethal 
phenotype of Xist knockout (Marahrens et al, 1997), which is known to be essential 
for initiation of X inactivation.   
 
The changes that do occur could be secondary effects of changes elsewhere in the 
genome, or genes directly regulated by CIZ1 but not via XCI, and seem to occur with 
similar frequency to the rest of the genome. The data show that 2.6% of genes across 
the whole genome are significantly changed following Ciz1 KO. Although these 
changes initially seemed to be unlinked, gene set enrichment analysis showed that 
many are targets of PRC1 and PRC2 subunits, or genes that are affected by 
knockdown of some of these subunits. This is an interesting observation since we 
also have evidence that the laying down of the H3K27me3 mark, for which PRC2 is 
responsible, is also disrupted in the absence of Ciz1. These observations begin to 
suggest that CIZ1 is involved in the normal function of the PRC1 and PRC2 
complexes. Interestingly, the RNA sequencing results revealed that expression of the 
PRC1 and PRC2 complexes subunits themselves is not affected by loss of Ciz1. This 
raises a whole new set of questions about the exact function of CIZ1 in relation to the 
action of polycomb repressive complexes. Further work should try to confirm 
observations which suggest that PRC1 and PRC2 complexes are functioning 
normally in the absence of Ciz1, using protein expression and immunolocalization 
studies in the first instance, since transcript levels do not always correlate with protein. 
In addition, although we have evidence that loss of Ciz1 disrupts the H3K27me3 
mark, no work has been done on the epigenetic mark laid down by the PRC1 
complex. It is therefore of interest to test whether ubiquitylation of H2AK119 (Chen et 
al, 2004) is in any way disrupted. 
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The lymphoma-like phenotype observed in female Ciz1 knockout mice could be 
linked to the observation that PRC1 and PRC2 targets are affected by loss of Ciz1. 
Female mice with Ciz1 knockout have enlarged spleens, liver and lungs (J. 
Ainscough, unpublished). Pathological characterisation (J. Roulsen, pathologist, 
unpublished data) of the lymphoid abnormalities led to description of the phenotype 
as consistent with follicular-type B cell lymphoma with reactive T cell infiltration. It is 
therefore of interest to investigate whether any of the affected PRC1 or PRC2 target 
genes could be linked to this phenotype. Of particular interest are the genes that are 
affected by knockdown of BMI1, since this PRC1 subunit and more specifically its 
overexpression, has been linked with lymphoma (Raaphorst, 2005). Although no 
overexpression of BMI1 itself is observed in our model, the majority of genes that are 
affected by knockdown of BMI1 show a downregulation of gene expression rather 
than the upregulation observed following knockout of BMI1 (Wiederschain et al, 2007) 
which, as previously mentioned, might suggest the gene expression observed 
following knockout of Ciz1 might be more characteristic of an overexpression of BMI1.  
 
In order to understand what drives development of the lymphoma-like phenotype in 
Ciz1 KO mice, analysis of the strong gender bias is likely to provide clues. Despite 
the fact that the lymphoma phenotype is observed exclusively in female mice, and as 
described above, this does not seem to be a consequence of compromised X 
chromosome inactivation. Nonetheless, there could be other intrinsic differences 
between female and male mice that could explain a female-only phenotype such as 
hormonal differences, for example. For this reason, BMI1 linked genes affected by 
Ciz1 KO were investigated for differences between female and male cell lines. This 
analysis revealed that in fact, approximately half of the 37 analysed genes are 
differentially affected by loss of Ciz1 in female cell lines compared to male. This is not 
a surprising result since even for humans significant differences in gene expression 
patterns have been reported for women and men (Zhang et al, 2009).    
 
From the total of 37 genes three candidates were identified, as they showed 
differences between female and male and also showed restoration of wild-type levels 
of expression following re-expression of Ciz1. These genes are Vegfc, Cxcl1 and 
Anxa3.  
 
Vascular endothelial growth factor C (Vegfc) is part of the VEGF family, which signal 
through receptor tyrosine kinases to induce angiogenesis, and lymphangiogenesis 
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(Ho and Kuo, 2007). In addition to playing a role in normal development, VEGFs also 
play crucial roles in the development and progression of cancer. Defined as one of 
the cancer hallmarks (Weinberg and Hanahan, 2000), tumours require a constant 
supply of oxygen and nutrients, and in order to ensure their supply they are capable 
of activating an “angiogenic switch”. This leads to an increase in the presence of 
inducers of angiogenesis such as VEGF, while reducing presence of angiogenic 
inhibitors. In line with this observation, many solid tumours as well as haematological 
malignancies, including several types of lymphoma and leukemia, are characterised 
by overexpression of VEGF (Ho and Kuo, 2007) (Gerber et al, 2003). Expression of 
this gene has also been found in malignant lymphoma, correlating with increased 
lymphangiogenesis (Kadowaki et al, 2005). Interestingly, while expression of Vegfc 
is upregulated in the Ciz1 KO female cell line, with increased lymphangiogenesis 
observed in the spleen of female Ciz1 KO mice. The same gene is downregulated in 
the male cell line, and might therefore contribute to the gender-specific phenotype.  
 
Cxcl1 encodes the chemokine ligand 1 protein, which belongs to the CXC chemokine 
family. It is expressed by macrophages, neutrophils and epithelial cells and it plays a 
role in inflammation, mainly through chemoattraction of neutrophils (De Filippo et al, 
2013). There is also evidence that secretion of CXCL1 from epithelial and endothelial 
cells induces angiogenesis. Just like the Vegfc gene, Cxcl1 is also upregulated in the 
female cell line but downregulated in the male. Increased expression of Cxcl1 has 
also been reported in follicular lymphoma (Glas et al, 2007), coinciding with the 
pathologist report on the type of lymphoma observed in the Ciz1 KO female mice.  
 
Finally, Anxa3 encodes the annexin 3 (ANXA3) protein, and belongs to the annexin 
family, which plays a role in cellular growth. No direct links have been established 
between this gene and lymphoma. It has however been linked with tumour growth 
related functions, specifically in hepatocellular carcinoma. However, given the fact 
that Anxa3 is downregulated in female cells following knockout of Ciz1 rather than 
upregulated which would be of interest, this gene is of no further interest for the 
purpose of this thesis.  
 
In addition to the BMI1–linked genes analysis, the immune system gene ontology 
analysis provided additional candidate genes which might contribute to the 
lymphoma-like phenotype. A good example is the Cd34 gene, which is upregulated 
in the female cell lines and downregulated in the male cells. Cd34 is a cell surface 
	
	
	
	
	
	
94	
glycoprotein with a role in a cell-cell adhesion and is expressed on the surface of 
lymph node high endothelial venules (van Zante et al, 2003). It plays an essential role 
in the infiltration of T-cells into lymph nodes, which has been observed in the mouse 
Ciz1 KO phenotype. The CD34 protein binds to the lymphocyte receptor L-selectin, 
expressed on the surface of T cells, allowing tethering and rolling along the 
endothelial wall and into the lymph node (Girard et al, 2012). Although no causative 
effects can be concluded from this gene expression analysis, these observations 
suggest that within the genes that are affected by knockout of Ciz1, there are some 
with known functions that could underlie the lymphoma-like phenotype and that in 
addition, show different expression patterns in female versus male cell lines. To 
understand cause and effect the candidate genes would need to be validated in 
animal models.   
 
The RNA sequencing results have provided large amounts of information on the 
effects that loss of Ciz1 has on gene expression, and I have selected a subset to 
investigate here. Analysis of all of the results is beyond the scope of this thesis, 
however, I have found some very promising avenues, which could become the 
subject of further research. This data could help understand the specific biological 
functions of CIZ1 both in a wild-type scenario such as cell-cycle and possibly 
polycomb repressive complexes related functions, as well as in the context of 
pathological conditions such as Alzheimer’s disease or cancer.  
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CHAPTER 6. DISCUSSION  
	
The nuclear matrix protein CIZ1 has been linked with devastating diseases such as 
several types of cancer, including breast (den Hollander et al, 2006) and lung cancer 
(Higgins et al., 2012), as well as neurological conditions such as Alzheimer’s disease 
(Dahmcke et al, 2008) and cervical dystonia (Xiao et al, 2012). It is therefore of 
importance to understand the biological functions of CIZ1, in addition to the already 
known role in the cell cycle (Coverley et al, 2005). By understanding the normal 
functions of the protein in different biological pathways we might obtain information 
on how disruption of the protein is linked with the development of disease.  
 
Previous research has shown that CIZ1 is localized to the Xi and that in its absence, 
the long non-coding RNA, Xist, which is essential for initiation of X chromosome 
inactivation, becomes delocalised from the inactive X (Ridings-Figueroa, 
unpublished). The exact function that CIZ1 exerts at this site is unknown and therefore 
became the subject of my research. Investigating the function of CIZ1 in the context 
of X chromosome inactivation is scientifically very interesting, not just to the X 
chromosome inactivation field, but also more widely as X chromosome inactivation 
has long been used as a model for the study of chromatin remodeling and epigenetic 
silencing, processes which are essential for cell survival and are known to become 
disrupted in the context of disease (Moss and Wallrath, 2007). In addition, the 
importance of nuclear matrix proteins in X inactivation has also become a matter of 
interest in the field (Hasegawa et al, 2010) (Hasegawa et al, 2011). This research 
could therefore add CIZ1 to the list of nuclear matrix proteins with known functions in 
X inactivation.  
 
Results from my investigation suggest that CIZ1 might have important links with the 
functions of PRC1 and PRC2, complexes which are central to the epigenetic silencing 
of the inactive X chromosome (Lund et al, 2004). This is further supported by 
observations that in the absence of CIZ1 the H3K27me3, laid down by the PRC2 
complex, is disrupted, at least to a certain extent. It is however unclear how exactly 
this disruption occurs. Other studies suggest that maintenance of this epigenetic mark 
is coincident with movement of the inactive X chromosome to the perinucleolar ring 
during S-phase, and that the H3K27me3 is deposited on the newly synthesized DNA 
(Zhang et al, 2007). In the absence of Xist, movement to the perinucleolar ring fails 
to occur (Zhang et al, 2007). Initial studies suggested direct binding of Xist to PRCs 
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(Zhao et al, 2009) but more recent work argue against by showing spatial separation 
between Xist and polycomb repressive complexes (Cerase et al, 2014). In a similar 
way, knockdown of the long non-coding RNA Firre, results in disruption of 
perinucleolar localization of the Xi as well as disruption of the H3K27me mark (Yang 
et al, 2015).  
 
Strikingly, evidence collected in the Coverley labs shows that movement of the Xi to 
the perinucleolar ring during S-phase is also dependent on the presence of CIZ1 
(Scott, unpublished). By putting these observations together, it is possible to bring 
forward a hypothesis for the function of CIZ1 in this process. If one assumed that the 
PRC2 factories, which are responsible for the laying down of the H3K27me3 mark, 
are located at the perinucleolar ring then it could be possible that CIZ1, likely in 
conjunction with other players such as Xist or other nuclear matrix proteins, could 
mediate the movement of the inactive X chromosome to the site, and that, in its 
absence, the ‘transport chain’ becomes disrupted failing to deliver template to the 
PRC2 factory. Whether CIZ1 constitutes an adaptor or linker molecule between the 
Xi and this transport chain, which could possibly be the nuclear matrix itself, or 
whether it is part of the transport chain itself remains unknown. In addition, the type 
of interaction, direct or indirect, that exists between CIZ1 and the Xi is also unknown.  
 
The proposed hypothesis is supported by my observation that although many of the 
PRC1 and PRC2 target genes are affected by loss of CIZ1, the PRC1 and PRC2 
subunits themselves do not show any differences in gene expression in the absence 
of Ciz1. Future work would need to extend this analysis from transcript to protein, and 
ask whether PRC components, including those that lay down H3K27me3 (PRC2) and 
H2AK119ub1 (PRC1) are present at similar levels and similar locations in WT and 
Ciz1 KO cells. If so, failure of template to visit those locations would be a viable 
hypothesis. 
 
If this proposition is correct, one could expect that this function of CIZ1 in relation to 
polycomb repressive complexes might extend not just to the process of X inactivation 
but also to the rest of the genome, as suggested by my whole genome analysis. This 
could offer an explanation for the overall disruption of the H3K27me3 mark across 
the whole nucleus in one of the subject cell types in this thesis. It is however likely 
that in the absence of CIZ1 other players, possibly other nuclear matrix proteins, are 
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able to compensate or at least partially substitute CIZ1 in its absence, since both the 
Ciz1 KO embryo and Ciz1 KO derived cell lines are able to survive.  
 
It is also possible that different mechanisms could be at work in the embryo compared 
to somatic cells, as well as between cell types. In the absence of CIZ1 100% of female 
mice develop a lymphoma-like phenotype, similar to B-cell follicular lymphoma, 
suggesting that cell types involved in this condition could be more susceptible to loss 
of CIZ1 compared to others. In fact, polycomb genes have been reported to be 
essential for B-cell development and differentiation and are suggested to have 
important roles in the initiation and progression of lymphoma (Wang et al, 2015). 
 
Future experiments should aim to validate the observation that loss of CIZ1 affects 
levels of expression of PRC1 and PRC2 target genes. This could be done through 
qPCR and ideally should also be validated at the protein level through a Western blot. 
In addition, it would be of interest to use antibodies against different components of 
the PRC1 and PRC2 complexes and test whether they colocalise with CIZ1 at 
different stages of the cell cycle or at the perinucleolar ring and whether normal 
localization of the PRC components is in any way disrupted in the absence of CIZ1. 
Protein-protein interaction assays could also be performed to test for interactions 
between CIZ1 and PRC components. Furthermore, I would also test whether loss of 
CIZ1 does in fact only affect the H3K27me3 mark laid down by PRC2 or whether it 
also disrupts the H2AK119 ubiquitination mark laid down by PRC1. If the importance 
of CIZ1 in the normal functioning of PRC components was validated it would be 
important to then ask whether the numerous links that CIZ1 has with several types of 
cancer are underlined by this function. A more detailed analysis of the RNA 
sequencing results would be useful in this matter. 
 
In conclusion, my analysis has opened up an exciting line of research which could 
shed new light on the molecular function of CIZ1, and with it, the mechanisms that 
are deregulated in its absence and which result in development of malignant 
conditions.  
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LIST OF ABBREVIATIONS 
	
Abbreviation Term 
XCI X chromosome inactivation 
PRC Polycomb repressive complexes 
lncRNA Long non-coding RNA 
RNAseq RNA sequencing 
Xic X inactivation centre 
Xp Paternal X chromosome 
Xm Maternal X chromosome 
rXCI Random X chromosome inactivation 
Xi Inactive X chromosome 
mPEFs Mouse primary embryonic fibroblasts 
GSEA Gene set enrichment analysis software 
H3K27me3 Trimethylated lysine residue at position 27 in 
the protein histone H3 
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